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ABSTRACT 
          Rationale   
The use of vaginal products is associated with increased HIV acquisition risk, but the 
mechanism is not fully understood. Vaginal practices entail the use of a wide variety of 
products which can alter the vaginal environment to achieve a desired state. Strong 
motivations for vaginal practices include women’s desire to maintain stable relationships, 
manage health, hygiene and sexuality. This adjustment of the vaginal microenvironment may 
increase HIV acquisition risk. High levels of inflammation and immune activation in the 
female genital tract are associated with a threefold increase in HIV acquisition risk. We 
hypothesized that intravaginal insertion products (IVIPs) may be linked to high levels of 
inflammation and immune activation in the female genital tract which may subsequently 
lead to an increased risk of HIV acquisition 
          Objective  
The pH of  the IVIPs (Kuber, Snuff, Alum, Savlon and Rose water) was measured and the 
cytotoxicity of the IVIPs was evaluated by determining their effect on cell viability at 
different dilutions (Neat/stock, 1/5, 1/10, 1/100 and 1/1000). The mechanisms by which 
potassium aluminium sulfate (“Alum”) and smokeless tobacco (“snuff”) impact cellular 
activation and inflammation were investigated using peripheral blood mononuclear cells 
(PBMCs) in vitro.  
          Methods  
The pH of alum, snuff, kuber, savlon and rose water was measured at different dilutions 
(Neat/Stock, 1/5, 1/10, 1/100 and 1/1000). The effect of the IVIPs on cell viability was 
determined by exposing PBMCs to the different dilutions of IVIPs mentioned above. 
PBMCs from 26 HIV-negative healthy donors were unstimulated (negative control) or 
stimulated for 3 hours at 37°C with 1/1000 dilutions of 450 mg/ml of alum or snuff and 
10µg/ml of PHA (positive control). The PBMC supernatants were collected following 
PBMC stimulation, and eleven cytokines were measured from 12 of the 26 PBMC 
supernatants. Pro-inflammatory (IL-1β, TNF-α, IL-6), chemokines (IL-8, IP-10, MIP-1α, 
MIP-1β, MCP-1), hematopoietic (IL-7, GM-CSF) and regulatory (IL-10) cytokines were 
measured using Bio-Plex multiplex assay. The activation status of T lymphocytes was 
determined by evaluating CD38+, HLA-DR+, dual expression of CD38+HLA-DR+ and 
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chemokine receptor CCR5+ expression from CD4+ and CD8+ T cells using flow cytometry 
assay.  
          Results  
Alum stock solution was acidic with a pH of 2.62 whereas the snuff stock solution was basic 
with a pH of 9.11. Alum and savlon were found to have high cytotoxicity. Snuff exposed 
cell resulted in a significantly increased CCR5 chemokine expression in CD4+ T cells when 
compared to the unexposed cells (p=0.0483) and also when compared to alum exposed cells 
(p=0.0446). However, snuff exposure did not significantly increase any of the activation 
markers in CD8+ T cells and it did not change the inflammatory cytokine profile. In CD8+ T 
lymphocytes the CD38+ biomarker was significantly more expressed in unexposed cells 
compared to the alum exposed cells (p=0.0185). Alum exposed cells significantly increased 
expression of HLADR+ (P=0.0348) and also the dual expression of CD38+HLA-DR+in CD8+ 
T cells (p=0.0208) when compared to the unexposed cells and was also associated with 
significantly high levels of cytokines IP-10 (p=0.039), MCP-1 (P=0.0024), MIP-1α 
(p=0.0005), IL-6 (P=0.0005), TNF-α (P=0.0020), IL-7 (P=0.0005) and GM-SCF (P=0.0005) 
when compared to the unexposed cells.   
         Conclusion 
This study is the first of its kind to identify a possible link between intravaginal insertion 
products and inflammation. Alum, in particular, was more inflammatory compared to snuff. 
These findings may help explain the previous observations of an increased HIV acquisition 
risk in IVIP users. Future research can extend the current pilot study on an invitro human 
vaginal epithelial cell model. Knowledge from this work and future studies is crucial in 
developing new female-initiated interventions for preventing HIV acquisition.  
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW. 
        1.1 Introduction 
1.1.1 Global HIV epidemiology 
Human immunodeficiency virus (HIV) and Acquired immunodeficiency syndrome (AIDS) 
have been the most critical public health pandemic that has threatened human survival and 
security since its first discovery in 1981(Gottlieb et al., 1981). Approximately 77.3 million 
people have been infected with HIV since the start of the epidemic, and it has claimed 35.4 
million lives through AIDS-related illnesses(UNAIDS, 2018). According to the UNAIDS 
report, HIV infections are currently estimated to be 36.9 million worldwide, with 1.8 million 
new HIV infections in 2017 or about 5000 new infections per day (UNAIDS, 2018). 
Although significant progress has been made since the antiretroviral therapy (ART) rollout; 
with an estimated 21.7 million on ART and 940,000 people dying of AIDS in 2017, a 47% 
decrease from 3.4 million in 1996, HIV remains a leading cause of death worldwide and the 
leading cause of death globally among women of reproductive age (UNAIDS, 2018).  
 
1.1.2 HIV epidemic in Sub-Saharan Africa 
Developing countries are profoundly affected by the HIV epidemic with more than 90% HIV 
infections, a more massive toll (70%) of these infections being from Africa (UNAIDS, 
2018). Sub-Saharan Africa (SSA) is the greatly affected region with 19.0 million HIV 
infections (UNAIDS, 2018) and one of the prime causes of death is HIV/AIDS. There were 
960 000 reported new HIV infections with 470 000 people who lost their lives due to AIDS-
related causes in 2015, with only 54% of the population on ART. Figure 1.1 shows the adult 
prevalence of HIV globally, with SSA having the highest HIV prevalence. 
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Figure 1. 1. Adult prevalence of HIV infection in Sub-Saharan Africa compared to other 
geographic regions. Dark blue colour indicates areas with the highest prevalence, whereas 
the light blue shades indicate areas with the lowest prevalence. Sub-Saharan Africa has more 
than two-thirds of all people living with HIV globally (figure adapted from UNAIDS, 2017). 
 
1.1.3 HIV Epidemic in South Africa 
South Africa remains the epicenter of the HIV epidemic and has the highest number of 
people living with HIV in the world (7.2 million) (UNAIDS, 2018). Although SA is home 
to approximately 1% of the world’s population, it contributes 14% of the global HIV 
infection burden, which is about 1000 new infections a day (UNAIDS, 2018). In 2015, 7 
million people were living with HIV, with 380 000 new infections and 180 000 people dying 
from AIDS-related deaths (UNAIDS, 2015). The country invests $1.5 billion yearly towards 
HIV/AIDS programs, it has the most extensive antiretroviral therapy program globally. 
However, with all the prevention programs implemented, the HIV prevalence in the general 
population is still high (19.2%), but it varies from region to region. KwaZulu-Natal (KZN) 
has the highest HIV prevalence of almost 25.2% compared to other provinces like Northern 
Cape and Western Cape with 13.9% and 12.6% prevalence, respectively (HSRC, 2018).  
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1.1.4 HIV epidemic in KwaZulu-Natal 
KwaZulu-Natal (KZN) is the second largest province in South Africa and the most 
vulnerable to HIV/AIDS, with the highest infection rate and therefore referred to as the 
epicenter of HIV/AIDS (Kiepiela et al., 2014). In South Africa, there are 12 Districts (Harry 
Gwala, uMgungundlovu, eThekwini, uThukela, iLembe, Zululand, Ehlanzeni, Gert Sibande, 
Ugu, eHlanzeni, King Cetshwayo and Buffalo city) with the highest HIV prevalence and 
KZN province having the most affected districts (Woldesenbet et al., 2018). 
High levels of migration to urban areas by the rural population in KZN is accompanied by 
high levels of sexual activity outside of the primary relationship (Collinson et al., 2007). 
These extra sexual activities often lead to increased risk of acquiring HIV, with resultant 
progression to AIDS and leading to AIDS-related deaths. Deaths often result in a multitude 
of orphans, most of whom have no means of surviving, so they depend on transactional 
relationships with older sexual partners for survival, thus exposing themselves to increased 
risk of acquiring HIV-1 (Meyer, 2013). 
 
1.1.5 HIV infection in women 
One of the significant disparities in HIV infectivity is gender with higher gender imbalance 
observed in profoundly affected regions such as SSA. A disproportionate impact of the HIV 
epidemic is found in women; women are four times more likely to be infected with HIV 
compared to men. Not only do young women aged 15-24 years have HIV rates higher than 
their male peers, but they also acquire HIV infection five to seven years earlier than their 
male peers (Karim et al., 2010). According to a UNAIDS report, adolescent girls and young 
women accounted for 20% of new HIV infections in 2015 globally (UNAIDS, 2016), whereas 
in SSA 25% of new HIV infections were observed in adolescent girls and young women. 
That study further showed that among adults, 56% of new HIV infections occurred in 
women, suggesting that women are at a higher HIV risk compared to men. A recent cross-
sectional household survey of randomly selected individuals aged 15-49 years in two 
neighboring sub-districts with a high burden of HIV infection in KZN reported HIV 
prevalence of 59.8% in women aged 25-40 years, 40.3% in men aged 25-40 years, 22.3% in 
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women younger than 25 years, and 7.6% in men younger than 25 years (Figure 1.2, 
(Kharsany et al., 2018)). They further suggested that sexual partnering between young 
women below the age of 25 and older men aged 25-40 years, who might have acquired HIV 
from women of similar age group, is a key feature of the sexual networks driving 
transmission in young women (Kharsany et al., 2018). 
 
 
 
Figure 1. 2. Shows age and gender-specific HIV prevalence in a survey carried out in 2 sub-
districts of KZN (Kharsany et al., 2018). HIV prevalence in women aged 15-24 years was 
22.3% (20.2-24.4) compared with 7.6% (6.0-9.3; p<0.0001) in men of the same age. This 
disproportionately high HIV prevalence in females versus male peers is observed from the 
age of 15 years up to more than 30 years whereas the prevalence in females is more than 70% 
at age 31-32 years. 
 
1.1.6 Why are young women so vulnerable to HIV infection? 
1.1.6.1 Economic status 
Young women from poor backgrounds are determined to come out of poverty, and often 
have little or no access to education (Fetters et al., 1998a). These women exchange sex for 
money and food and become vulnerable in quest of basic income  (Stoebenau et al., 2016). 
Hence, these relations often expose young women to unsafe sexual behaviors, low condom 
use and an increased risk of sexually transmitted infections (Glynn et al., 2001). This 
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unfavorable economic status forces women to depend on their male companions to provide 
for them and their children (Heise and Elias, 1995). 
Poverty has resulted in urbanisation in search of employment. Urban settings have a higher 
HIV prevalence than rural settings, with sex work common in poverty stricken women 
(Dodoo et al., 2007). On the other hand, economically empowered girls tend to be involved 
in safer sexual behaviors and remain in school leading to a reduced HIV prevalence and 
incidence (Cluver et al., 2016, Taaffe et al., 2016). 
 
1.1.6.2 Gender-Based Violence and Gender inequality 
Physical and sexual violence against women and children is a significant crisis facing 
southern Africa, and it is linked to perceptions of male superiority (Jewkes et al., 2010). 
South Africa is said to have the highest number of cases of gender-based violence in the 
world, and these cases include rape and domestic violence (Onyejekwe, 2004). Usually, men 
exert power over women through sexuality and women who went through physical and 
sexual partner violence were reported to be 1.5 times more likely to acquire HIV compared 
to women who had not experienced violence (García-Moreno, 2013). Intimate partner 
violence has been shown to inflict fear in women and has imposed difficulties in the uptake 
of HIV testing and counseling, disclosing HIV status, treatment uptake and adherence 
(Durevall and Lindskog, 2015, Hatcher et al., 2014). Additionally, violence (physical, 
emotional, verbal, economic) has been linked to low adherence to Pre-exposure prophylaxis 
(PrEP) medication, thus disrupting HIV prevention strategies (Roberts et al., 2016). 
Younger women are four times more likely to be sexually assaulted than older women 
(Snyder, 2000) and younger girls who have been victims of rape before the age of 18 are 
more likely to experience subsequent sexual assaults as adults (Gidycz et al., 2001). Rape 
carries an increased risk of HIV acquisition compared to consensual sex because it is a forced 
sexual act and may usually cause genital trauma that increases the risk of HIV infection. In 
the case of virgins and child rape, the risk of HIV acquisition is heightened because this 
causes severe injuries in the vaginal epithelium which serve as entry points for HIV (Van 
der Straten et al., 1995). Sexual abuse of children has been linked to increased risk of 
engagement in high-risk behavior such as having multiple sexual partners, the use of drugs 
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and alcohol which leads to risky behavior and increases the chances of HIV acquisition 
(Dembo et al., 1992, Laga et al., 2001, Pettifor et al., 2004, Stöckl et al., 2013). Women from 
limited resource settings are greatly affected by violence because they have limited means 
to secure legal rights including women working as sex workers, who are at a particularly 
increased risk of physical and sexual abuse (Dearing and Hequembourg, 2014). 
 
1.1.6.3 Lack of access to healthcare 
In settings where HIV services are available, they are perceived as primarily for married 
women or women older than 18 women. Health care providers lack youth-friendly services 
(Mantell et al., 2009). The Lack of access to reproductive health (SRH) services means that 
women are not able to exercise their sexual and reproductive health rights (SRHR) (Karim 
et al., 2010). The Adolescent and Youth Friendly Service (AYFS) approach has been 
promoted in South Africa by the National Department of Health and partners, as a means of 
standardizing the quality of adolescent health services in the country. Currently, the facilities 
have the essential components for general service delivery in place, but adolescent-specific 
service provision is lacking (Lince-Deroche et al., 2015). 
 
1.1.6.4 Early sexual debut 
The early sexual debut has been linked to an increased risk of HIV acquisition (Pettifor et 
al., 2004). Most biologically based studies have found the risk of contracting HIV through 
heterosexual intercourse to be higher for women compared to men (UNAIDS, 2018). 
Physiological and immunological immaturity of the female genital tract (FGT) at the time of 
first sexual debut increases young women’s susceptibility to HIV infection and other 
sexually transmitted infections (STIs). An immature FGT may lack tolerance to semen 
exposure, therefore eliciting an immune response that results in the recruitment of cells, 
including HIV target cells, to the site of semen exposure and thus predisposes women to 
increased HIV infection risk (Kigozi et al., 2009). In addition, an early sexual debut exposes 
the woman to an increased HIV infection risk due to an extended sexual activity duration 
because the early sexual exposure would mean a more extended sexual history in one’s 
lifetime and more prolonged HIV infection risk exposure (Pettifor et al., 2004, Stöckl et al., 
2013). 
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1.1.7 Biological factors that increase the risk of HIV susceptibility in women 
While the causes of women's vulnerability to HIV has not yet been fully elucidated, the 
disproportionate impact of the HIV epidemic on women suggest that other factors beyond 
behavior may be contributing to the heightened vulnerability in young women. The exposed 
mucosal surface of the vagina may facilitate HIV acquisition. Further, the high levels of 
activated immune cells in the female genital tract, and the increased expression of HIV co-
receptors in cervical cells compared to foreskin cells may also explain why women have a 
higher per-sexual act risk of HIV acquisition than men (Boily et al., 2009). 
 
1.1.7.1 Cervical ectopy 
The extension of the columnar epithelium from the endocervical canal towards the 
ectocervix is termed cervical ectopy, and some studies have found this condition to be a risk 
factor for HIV acquisition (Venkatesh and Cu‐Uvin, 2013). The endocervical columnar 
epithelium is thin from having a single layer of glandular cells in close association with 
underlying vascular cervical stroma whereas the ectocervix is covered by a stratified 
squamous epithelium (Jacobson et al., 2000). The ectopic tissue allows easy access to the 
blood and lymphatic systems. Therefore there is a decrease mucosal barrier integrity that 
allows for easy access to sexually transmitted infections, including HIV (Collier et al., 1995, 
Critchlow et al., 1995, Ritter et al., 1988). Cervical ectopy is more common in adolescent 
girls, pregnant women, and in women on hormonal contraceptives. Hence, Adolescent girls 
are likely to have larger areas of ectopy or immature epithelium that could increase the 
chances of acquiring HIV and other STIs (Moscicki et al., 2001). A study by Moench et al. 
(2001) has found that immature cervical epithelium in healthy young women was associated 
with cervicovaginal inflammatory and regulatory cytokines and chemokines. 
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Figure 1. 3. Shows the female reproductive system (Thomas, 2013). 
 
1.1.7.2 Mucosal Surface of the vagina 
Although vaginal intercourse carries a lower HIV transmission probability per exposure 
event (1 in 200 to 1 in 2000) than anal intercourse or parenteral inoculation, it contributes to 
more HIV incident cases (Hladik and Doncel, 2010). Women mostly engage in heterosexual 
intercourse which carries a higher risk of HIV infection, because during the intercourse a 
large inoculum of infected seminal fluid is deposited into the vagina which has a large 
susceptible surface area and can stay for several hours inside the vagina, thus extending the 
duration of the HIV infection risk. Heterosexual intercourse can also result in micro-
abrasions in the vagina, which can serve as an entry point for the virus to enter the 
bloodstream (Powers et al., 2008). The female vaginal membrane has higher permeability 
compared to that of the penis (Baden and Wach, 1998, Yi et al., 2013). Therefore, the risk 
factors associated with successful heterosexual transmission of HIV infection include: (i) 
Vaginal epithelial damage as a result of trauma-related abrasions or lesions caused by the 
presence of STIs (Draughon, 2012); (ii) viral load in plasma and in genital secretions 
(Morrison et al., 2010, Wilson et al., 2008); (iii) the use of hormonal contraceptives or 
hormonal changes associated with menstruation which cause the thinning of the genital 
epithelium (Brawner et al., 2016a, Ngcapu et al., 2015); and (iv) abundance of activated HIV 
target cells (CD4+ T cells and Langerhans cells expressing CCR5) recruited along an 
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inflammatory gradient as a result of trauma or sexually transmitted infections (Rancez et al., 
2012, Stieh et al., 2014). 
 
1.1.7.3 Inflammation and immune activation in the female genital tract 
Female genital tract (FGT) inflammation is the response of FGT tissue to injury or pathogen 
invasion, this response involves a well-organized cascade of fluid and cellular changes 
within the tissue. The affected FGT tissue becomes red and swollen due to increased blood 
flow and due to fluid accumulation, respectively. The changes are a result of vascular 
response to inflammation, and the response involves changes in vessel capacity and 
consequently blood flow. Increased blood flow results from the vessel dilation and the 
hydrostatic pressure increase, which also causes the escape of plasma proteins into the 
extracellular space due to vascular permeability increase. The retraction of FGT endothelial 
cells caused by chemical mediators leaves intercellular gaps between the cells. These gaps 
often lead to unfavorable development of chronic inflammation. Chemotaxis is the process 
of the movement of leukocytes to the area of inflammation. Monocytes and granulocytes 
respond to chemotactic factors and move along a concentration gradient. Leukocytes play 
an important role in the inflammatory response of microbial killing after the immune cell 
activation. The activation of the immune response due to the presence of pathogens, irritation 
and tissue damage leads to the release of cytokines, which initiate the acute phase response 
of inflammation (Haase, 2010). Physical contact between cells and solid particles leads to 
phagocytosis and the release of antibacterial proteins such as defensins and lysosomes, 
which affect the bacterial permeability by causing the bacteria to leak to death. The release 
of the lysosomal products from the cell damages local tissue and can kill microorganisms 
outside the cell. Inflammation of prolonged duration is termed chronic inflammation and it 
is characterised by tissue destruction and tissue repair substances found at the same time 
(Janeway et al., 1996). 
 
1.1.8 Genital inflammation and immune activation’s association with increased risk of HIV 
acquisition. 
Vaginal epithelial cell damage or trauma from infections and irritation can cause immune 
activation in the female genital tract; this reaction can increase the expression of soluble 
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immune proteins. The presence of immune proteins in the FGT triggers the expression of 
HIV co-receptors to the cervicovaginal mucosa and thus increasing susceptibility to HIV 
infection (Fichorova et al., 2001a). Chemokines can be found constitutively or be induced; 
therefore, they are classified according to their function, i.e., homeostatic and inflammatory, 
respectively. Inflammatory chemokines MIP-1α, MIP-1β, RANTES, and CCL5 induce the 
expression of CCR5 receptors within the CD4 and CD8 T cell subsets (Raport et al., 
1996).There is little or no expression of CCR5 in the naïve T cell population, but its primarily 
expressed on memory cells (Sato et al., 2007). Upon T cell activation, the expression of the 
inflammatory chemokine receptor is upregulated and HIV R5- tropic strains primarily target 
CCR5 T cells. Therefore, an increased density of target cells in the genital mucosa may 
contribute to increased HIV susceptibility (Margolis and Shattock, 2006). The presence of 
dendritic cells in the female genital mucosa can play a role in the HIV acquisition by taking 
up HIV with lectin-binding receptor DC-SIGN interaction with the HIV gp120 and thus 
infecting CD4 T cells in trans (McDonald et al., 2003, Turville et al., 2004).  Genital 
inflammation is multi-causal; however, it is still not completely understood, and some of the 
possible causes are discussed below.  
 
1.1.8.1 Possible causes of immune activation and inflammation in the FGT 
I. Sexually transmitted infections (STIs): 
Sexually transmitted infections are associated with inflammation, the inflammatory response 
in the FGT is important for sexual transmitted infection clearance. The genital inflammatory 
response is detrimental prior to HIV exposure as it increases the likelihood of acquiring HIV 
infection (Masson et al., 2015, Morrison et al., 2014), through predisposition of HIV co-
receptor CCR5. Some studies have established that inflammation is caused by bacterial 
pathogens such as Neisseria gonorrhoea, as well as viral and protozoan infections such as 
Herpes Simplex Virus (HSV)-2, and Chlamydia trachomatis (Chaban et al., 2014, Ghartey 
et al., 2014). Some STIs are asymptomatic therefore women harbour infections unknowingly 
resulting in genital inflammation and hence, increased HIV acquisition risk (Mlisana et al., 
2012). However, asymptomatic STIs can only account for 20% of the genital inflammation 
(Serwadda et al., 2003). HIV susceptibility is increased by concurrent sexually transmitted 
infections (Schellenberg and Plummer, 2012).  
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Changes in vaginal pH may lead to opportunistic Staphylococcus aureus to stimulate the 
innate immune system in the vaginal epithelial cells through the secretion of exotoxins. A 
study conducted by Peterson et al. (2005), revealed that S. aureus causes a two-fold up-
regulation of genes coding chemokines or cytokines. Candida albicans is a polymorphic 
fungus that can be found in the vagina and it forms part of the normal constituents of the 
microflora and it is the cause of vaginal thrush. C. albicans can grow in different physical 
forms including unicellular yeast, pseaudohyphae, and hyphae. Based on C. albican's 
physical form it can be associated with infection (pseudo, pseaudohyphae, and hyphae) and 
it can also be associated with harmless colonization (unicellular yeast). Through the 
interactions between pattern recognition receptors (PRRs) found on the dendritic cell’s 
surface and pathogen-associate molecular patterns (PAMPS) found on the fungal cell wall, 
the dendritic cells are activated. This interaction results in the activation of different antigen 
specific immune responses and the recognition of C. ablicans is accompanied by the 
secretion of cytokines that drive the activation and differentiation of the naïve T-lymphocyte 
into one of the possible T-helper (Th) subsets (Richardson and Moyes, 2015). Schaller et al. 
(2005) showed that C. ablican’s strains activated interleukins, tumor necrosis alpha, and 
gamma interferons that are responsible for tissue damage of vaginal epithelial cells. Some 
STIs are ulcerative and the disruption of cervico-vaginal epithelial integrity by ulcerative 
genital diseases such as HSV or Haemophilusducreyi may increase HIV-1 acquisition risk 
by allowing direct lamina propria infection by HIV-1 (Chen, 2012). 
 
II. Changes in vaginal flora 
Bacterial Vaginosis (BV) a condition that is characterized by an imbalance in Lactobacilli 
bacteria in the vagina and it is the most common cause of vaginitis and a number of studies 
have linked BV to increased risk of HIV acquisition by compromising the vaginal epithelial 
integrity or by triggering the immune activation in the female genital tract through cytokine 
and chemokine upregulation (Low et al., 2011b, Spear et al., 2007). BV induces an 
inflammatory response by upregulating the secretion of pro-inflammatory cytokines, namely 
IL-6, IL-8, TNF-α, and IL-1β and also induces IL-12, IL-23 and p24 secretion and activation 
markers HLA-DR, CD86, CD83 and CD40 on dendritic cells, therefore, increasing the risk 
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of acquiring HIV infection (Masson et al., 2015). Hence, BV causes mucosal inflammation 
by activating the cervico-vaginal environment creating an HIV permissive environment 
(Thurman et al., 2015). 
 
Aerobic vaginitis (AV) is also caused by an imbalance in the vaginal bacteria i.e. disruption 
in the lactobacillus- dominated vaginal microbiota. However, AV is characterized by 
proliferation of enteric aerobic bacterial organisms including Staphylococcus aureus, 
Enteroccoci, Escherichia coli, and group B streptococcus; leukocytes and parabasal cell-
infiltration, over-inflammation, pH>6, itching and burning, red vaginal mucosal 
inflammation, dyspareunia, yellowish discharge and by an increased IL-1β and IL-6. AV is 
present in 2-25% of women and it is associated with STIs such as N. gonorrhoea, T. 
vaginalis, and C. trachomatis, which results in ascending genital inflammation and infection 
(Kaambo et al., 2018). 
III. Exposure to seminal proteins 
Greater fluctuations in vaginal flora are associated with frequent intercourse (Schwebke et 
al., 1999b). In the FGT the recruitment and activation of dendritic cells (DC), granulocytes, 
macrophages, and CD4+ T cells results from the chemokine/cytokine expression observed 
after sexual intercourse and may predispose women to the elevated risk of HIV acquisition 
(O'leary et al., 2004, Prakash et al., 2003). Gutsche et al. (2003) showed higher expression 
of IL-1β, IL-6, and Leukin inhibitory factor (LIF) in epithelial cells when cultured with 
seminal plasma. A study conducted by Sutherland et al. (2012) has revealed that the presence 
of seminal plasma in the cervical adenocarcinoma cells induced the expression of 
inflammatory COX-1 and COX-2, IL-6, IL-11, and chemokines CXCL1 and CXCL8. 
Seminal plasma interacts with human cervical and vaginal tissues to induce pro-
inflammatory cytokine production required for immune tolerance during conception 
(Sharkey et al., 2007).  
 
IV. Hormones 
Hormonal cycling, hormonal contraception use alter cervical immunity in different ways 
known to increase the risk of HIV acquisition through increased levels of pro-inflammatory 
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cytokines (Morrison et al., 2014). Reduced epithelial glycogen in the vagina decreases the 
lactic acid production resulting in the loss of its anti-inflammatory activities, therefore, 
resulting in a dysbiotic vaginal flora which is associated with inflammation (Wrenn et al., 
1968). Progesterone may cause adverse effects on the female genital tract resulting in an 
increased risk of HIV infection. Wira et al. (2015) showed that the mucosal barrier is 
compromised during the high progesterone luteal phase. Reduced estrogen levels after 
menopause can results in inflammation in the vagina. Depot medroxyprogesterone acetate 
(DMPA) is a risk factor for HIV acquisition through inflammation (Byrne et al., 2016, 
Murphy et al., 2015). 
 
V. Vaginal trauma and sexual trauma 
The vagina experiences both anatomic and physiological changes during sexual intercourse. 
Mucosal micro-abrasions and laceration have been observed in several women for up to 80 
hours after coitus, and this mucosal damage leads to inflammation which increases the risk 
of acquiring HIV (Astrup et al., 2012). The presence of cervico-vaginal lymphocytes which 
could be activated in response to injury increases the susceptibility to infection and 
dysregulation of epithelial tight junctions in the female genital tract, resulting in increased 
access for pathogens and increased permeability (Brawner et al., 2016b, Porter et al., 2016). 
Inflammation can result in increased blood flow and elevated capillary pressure which 
increases frictional tension in the vagina (Berman and Bassuk, 2002). Sexual assaults result 
in vaginal wounds which are damaged mucosal surfaces of the vagina, which are estimated 
to occur in 22-90% of all sexual assaults (Draughon, 2012). Wound healing consists of the 
sequential release of cytokines, chemokines, proteases and growth factors by platelet, 
macrophages, neutrophils, and fibroblasts (Shah et al., 2012). The process of wound healing 
starts with inflammation that occurs as a result of sexual assaults and followed by the repair 
process which releases specific immune factors that that control inflammation and recruit 
specific cells for repairing the mucosa. Immune mediator’s improper/ untimely expression 
can result in delayed wound healing and increased susceptibility to pathogens such as HIV 
(Werner and Grose, 2003). 
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VI. Introduction of foreign matter into the vagina 
Introduction of foreign matter into the vagina is done for different reasons with the common 
reason being an adjustment to the labia, clitoris, vagina, or the vaginal environment. These 
acts are referred to as vaginal practices, and they include heating of the vulvar area, external 
washing, douching, external product application, intra-vaginal insertion, physical 
modifications, and oral ingestion (Scorgie et al., 2009). Some studies have looked at the 
biological trauma in the natural structure of the vagina and have found that microabrasions, 
lesions, and inflammation are caused by vaginal products introduced into the vagina 
(Brotman et al., 2008, Fashemi et al., 2013, Low et al., 2011b). 
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1.2 Literature review 
1.2.1 Vaginal practices 
Vaginal practices involves introduction of foreign matter into the vagina and a wide range 
of products is typically used for this practice, including personal hygiene products, a variety 
of medicines, commercially available products and other environmentally sourced items 
such as leaves, herbs and powdered stone (Allen et al., 2010, Hawes et al., 1996). Vaginal 
products are mainly used for sexual satisfaction of male partners who desire a warm, tight, 
and dry vagina, for increased sexual pleasure (Gafos et al., 2010). In some cases, intra-
vaginal practices may also be used as part of treatment for vaginal discharge, suspected STIs, 
and for hygiene purposes (Gresenguet et al., 1997). Vaginal practices are alleged to be linked 
to adverse health outcomes and increased susceptibility to BV and transmission of STIs 
including HIV, through disruption of genital mucosa, change in vaginal flora and by altering 
vaginal pH (Hilber et al., 2007, Myer et al., 2006). The association between increased HIV 
susceptibility and vaginal practices is possible but varying in epidemiologic studies (Low et 
al., 2011a). With very little knowledge about the impact of vaginal practices on the vaginal 
immune microenvironment, the understanding biological mechanism by which intra-vaginal 
products may influence women’s susceptibility to HIV is now critical to ensure the 
effectiveness of new HIV prevention methods.  
 
1.2.1.1 Epidemiology of vaginal practices and different types of vaginal practices 
There are many different types of vaginal products, which are used for different reasons. 
Vaginal practices prevalence is higher in places where male partners have a strong 
preference for dry sex (Beksinska et al., 1999). Women with multiple sexual partners, 
including female sex workers, are reported to frequently indulge in these practices (Scorgie 
et al., 2009). A number of factors cause women to use vaginal practices such as (i) vaginal 
cleansing, (ii) treatment of sexually transmitted infections (STIs) or vaginal discharge, (iii) 
prevention of pregnancy or to induce abortion, (iv) enhancement of sexual pleasure and (v) 
as a ‘love potion’ to attract or retain partners (Hilber et al., 2007). In SSA, the prevalence of 
vaginal practices ranges from 6 to 98%, and female sex workers reported the highest 
prevalence (Allen et al., 2010, Fonck et al., 2001). There are six distinct types of vaginal 
 
 
16 
 
practices which have been previously identified: (i) external washing with or without 
products (ii) external application of products around the vulva, (iii) anatomical modification, 
(iv) intravaginal cleansing with or without products, (v) intravaginal insertion of products 
and (vi) oral ingestion of specific product to alter the vaginal environment (Hutchinson et 
al., 2007, Myer et al., 2006). 
 
1.2.1.2 Commonly used products in vaginal practices 
A variety of products are used in vaginal practices, and these products range from 
pharmaceutical, household, and traditional products. Several studies have documented the 
use of leaves and herbs (including tobacco) in vaginal practices, whereas other studies have 
documented detergent and antiseptic use. For this thesis, products previously identified as 
commonly used in the KZN province will be described. Some of the commonly used 
products in South Africa were discovered in Vulindlela, KZN, which is one of the highest 
burden HIV district in South Africa. Eleven group discussions (“boot camps”) were 
conducted between 2013 -2015 with 495 African females aged 13-24, and three targeted 
focus group discussions (FGDs) with 24 African females aged 16-25 (Humphries et al., 
2018).Products include Kuber chewing tobacco which is applied into the vagina for drying 
purposes; it contains ~20% nicotine, cannabidiol and delta 9-tetra cannabinol (THC); the 
primary ingredient is Indian hemp/marijuana). Alum (aluminium sulfate) is a colorless 
astringent compound, which is inserted vaginally for douching; also a common adjuvant 
used in vaccine preparations, known to stimulate the toll-like receptor (TLR) 7 inflammatory 
pathway and activate NF-Κb. Rose water (flavored water made from steeping rose petals 
into the water, used as a vaginal douche).Snuff (chewing tobacco; which is made from 
ground or pulverised tobacco leaves and contains nicotine, it is inserted vaginally as a sexual 
stimulant and a tightening agent). Table 1.1 summarises a list of vaginal products commonly 
used in KwaZulu-Natal, these products include Alum (Gafos et al., 2010), tobacco (Ghys et 
al., 2001) antiseptic liquids (McClelland et al., 2006, Myer et al., 2006) and rose water 
(Humphries et al., 2018). 
 
  
 
 
17 
 
 
Table 1. 1. Details of the commonly used intravaginal inserted products (IVIPs) 
IVIPs Ingredients Commercial 
uses 
Vaginal uses References  
Alum Potassium 
Aluminium 
sulfate 
(KAl(SO4)2) 
treatment of 
mouth ulcers, 
water 
purification, 
food 
preservative 
douching/ 
tighten 
(Gafos et al., 
2010, 
Humphries et 
al., 2018) 
Snuff Tobacco, 
ammonium 
carbonate, salt, 
preservatives 
smoking and 
chewing  
 
sexual 
stimulant/ 
tightening 
(Humphries et 
al., 2018) 
Kuber Scented Khaini 
leafy tobacco 
air freshener, 
chewing 
libido-
enhancing 
/Drying 
(Humphries et 
al., 2018, 
Waxman et al., 
2016)  
Rose water Distilled water 
with rose 
flavouring 
cooking, skin 
toner 
treating 
vaginal odour 
(Humphries et 
al., 2018) 
Savlon Chlorhexidine 
gluconate, 
cetrimide, n-
propyl alcohol 
benzyl benzoate 
antiseptic liquid douching (McClelland et 
al., 2006, Myer 
et al., 2006) 
Household 
products 
Lemon juice, 
vinegar, OMO 
Consumption, 
Detergents 
cleansing (Hilber et al., 
2010, Low et 
al., 2011a) 
 
1.2.2 Definition of a healthy female genital tract suitable for prevention of pathogenic 
microbes 
The genital mucosa is protected by multiple barriers such as mechanical barriers (tight 
junctions and mucosal epithelia) and chemical barriers (mucus, antimicrobial factors, and 
innate immune cells), together these barriers resist the invasion of the genital mucosa by 
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pathogens (Langbein et al., 2002, Marchiando et al., 2010). Intercellular spaces between 
epithelial cells are sealed by intact, tight junctions, therefore preventing paracellular 
penetration by viruses and pathogens. The multi-layered vaginal mucosal epithelia are 
stratified and supported by the fibrous connective tissue, and the lamina propria and 
epithelial cells provide immune functions by producing cytokines and antimicrobial factors 
that repel and kill microbial antigens (Sotolongo et al., 2012), whereas the endocervical 
mucosa is a monolayered epithelium. The disruption of tight epithelial junctions leads to the 
opening of paracellular spaces in between the epithelial cells and therefore leading to 
paracellular penetration by pathogens and viruses. This disruption is also associated with the 
upregulation of pro-inflammatory cytokines, thus increasing the acquisition risk of HIV. 
 
A healthy vagina is naturally acidic and has a pH below 4.5 (Ravel et al., 2011a). Vaginal 
epithelial cells metabolise glycogen to produce glucose under the estrogen influence, and 
after that, lactobacilli convert glucose to lactic acid (Hillier et al., 1992). Some lactobacilli 
species, particularly L. crispatus and L. jensenii can produce hydrogen peroxide (H2O2), 
which is toxic to many pathogenic microbes. However, it favors the growth of Lactobacillus 
species. Therefore, a healthy female genital environment is also dominated by Lactobacilli 
species. The capacity of lactobacilli to adhere and compete for adhesion sites in the vaginal 
epithelium and also to produce antimicrobial compounds (hydrogen peroxide, lactic acid, 
bacteriocin-like substances), is important in the impairment of colonization by pathogens 
such as E. coli, Candida species, Gardnerella vaginalis and Mobiluncus species (Borges et 
al., 2014). However, some studies have found that a lactobacilli dominated microbiome is 
likely found in European women whereas in African women a diverse microbial profile is 
displayed and therefore a healthy vaginal definition is not straightforward as ethnicity seem 
to be influencing the composition of vaginal microbiome (Ravel et al., 2011b, Zhou et al., 
2010, Zhou et al., 2009).  
 
An association between inadequate vaginal lactobacilli and the development of several STIs, 
including HIV, has been reported (Petrova et al., 2015, Petrova et al., 2013). An unhealthy 
vagina typically has an alkaline pH, higher numbers of Gardnerella vaginalis, Mycoplasma 
hominis, Prevotella, Peptostreptococcus, Mobiluncus, Bacteroides Atopobium vaginae and 
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Megaptera species (Borges et al., 2014). Bacterial Vaginosis is defined by the disequilibrium 
in the vaginal microbiota, with a decline in the number of lactobacilli species, increased pH, 
and inflammation. An illustration comparing a healthy vagina versus a vagina with BV is 
shown in Figure 1.4. 
 
 
 
Figure 1. 4.  Shows a comparison of a healthy vagina versus a vagina with BV. A healthy 
vagina is defined by an intact squamous epithelium, low pH and dominance of Lactobacilli 
species which produces lactic acid that inhibits the growth of anaerobic bacteria and helps 
maintain a low vaginal pH (< 4.5) which generates a non-inflammatory environment resulting 
into an eubiosis state. An unhealthy vagina can have high vaginal pH (>4.5), an environment 
that allows the growth of anaerobic bacteria leading to a pro-inflammatory and a dysbiotic 
environment that favours BV. 
 
1.2.3 Impact of vaginal products on vaginal health 
1.2.3.1 The impact of altering vaginal pH 
Some vaginal practices such as douching can potentially wash away good bacteria in the 
vagina as some of the products are antibacterial and therefore harsh for the vaginal 
environment resulting in the elimination of bacterial species in the vagina even the good 
Dendritic
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bacteria such as lactobacilli. Several vaginal products contain ingredients that are potentially 
harmful to the mucosal barrier of the FGT and may potentially influence susceptibility to 
HIV or STI infection by altering normal vaginal pH, which is typically acidic at pH 3.8- 4.5 
(O’Hanlon et al., 2013).  
 
A vaginal pH of less than 3.5 might be considered too acidic for the vagina as this pH might 
cause vaginal tissue disruption, which can lead to inflammation. Inflammation has been 
associated with increased risk of HIV infection acquisition, through pro-inflammatory 
factors such as IL-8 and MIP3-α which are associated with recruitment and activation of 
HIV target cells into the genital mucosa (Arnold et al., 2016). Whereas an elevated vaginal 
pH shifts the vaginal environment in favor of pathogenic microbiome such as Gardnerella 
vaginalis, where its overgrowth leads to the formation of an infected biofilm which then 
accommodates numerous gram-negative anaerobes (Hardy et al., 2015).Hence, BV, which 
has been associated with more than the three-fold increased risk of acquiring HIV infection 
(Cohen et al., 2012). The effect of vaginal insertion products on vaginal pH requires further 
investigation.  
 
1.2.3.2 Disruption of genital mucosa by vaginal products, cellular activation, inflammation 
and risk to HIV infection 
Some vaginal products used for the dry sex effect can disrupt the genital mucosa therefore 
leading to easy penetration of pathogens to the immune cells, which can lead to an increased 
risk of HIV acquisition (Hilber et al., 2010, Low et al., 2011b). The act of unlubricated sexual 
intercourse is termed “dry sex,” and women often engage in this type of sexual intercourse 
for the benefit of their male partners who desire tight and dry vaginas for increased sexual 
pleasure (Gafos et al., 2010). To achieve this “dry sex state,” women use a range of products 
such as environmental sourced herbs, powdered stone, house cleaning detergents, cloths, and 
commercially available products. However, the perception of dry sex may cause intense 
friction which is associated with micro-abrasions in the vaginal epithelium leading to a 
broken mucosal barrier that allows for pathogen penetration leading to the recruitment of 
pro-inflammatory cytokines and an inflamed site thus increasing HIV acquisition risk 
(Masson et al., 2015). Vaginal products used to achieve dry sex state may also decrease or 
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eliminate protective bacterial species responsible for pathogen eradication in the vagina 
(Martino and Vermund, 2002).  
 
1.2.3.3 The effect of vaginal products on the vaginal microbiome 
The impact of vaginal insertion products on the vaginal microbiome is unknown. However, 
intravaginal practices are associated with the disturbance of vaginal flora which is termed 
vaginal dysbiosis (Brotman et al., 2008, McClelland et al., 2006). Some studies have found 
an association between BV and vaginal practices (Brotman et al., 2008, McClelland et al., 
2006). However, Rugpao et al. (2008) found no correlation between cleaning inside the 
vagina and developing BV. Vaginal practices have not only been linked to vaginal dysbiosis, 
but also other STIs. A study by Tsai et al. (2009) demonstrated that the chances of acquiring 
STIs were 1.8 times greater for participants who douched regularly compared to participants 
who never douched or those who douched occasionally. On the other hand, Ness et al. (2005) 
found that irregular douching was not associated with gonococcal and chlamydial infections. 
Intravaginal practices have also been linked to the risk of HIV infection (Ghys et al., 2001, 
McClelland et al., 2006, Myer et al., 2006, Van de Wijgert et al., 2000). However, Myer et 
al. (2006) found no correlation between HIV acquisition and vaginal practices. There is a 
gap in the literature about the mucosal activation following exposure to intravaginal insertion 
products and sexual activity. Several studies have suggested a link between IVIPs and 
increased susceptibility to HIV infection (Low et al., 2011b). However, other studies have 
not found any association. While some cohort studies have demonstrated significant 
associations between IVIPs and HIV risk (Brotman et al., 2008, Fashemi et al., 2013, Low 
et al., 2011b), the mechanism by which IVIPs impact vaginal microenvironment have been 
speculated in a few studies (Brotman et al., 2008, Fashemi et al., 2013, Fichorova et al., 
2001b, Francis et al., 2016). However, the actual mechanisms in which IVIPs impact the 
mucosal microenvironment are not known and the direct causal pathway that links IVIPs 
with HIV acquisition has not yet been demonstrated. A summary of the postulated effects of 
vaginal insertion products on the vaginal environment and health is illustrated in the figure 
below (Figure 1.5) 
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Figure 1. 5. Shows a conceptual diagram of the causal pathway of vaginal practices, BV, STIs 
and HIV susceptibility. Young women insert products into their vaginas mainly for sexual 
enhancement, treatment of STIs and personal hygiene; this is suspected of leading to vaginal 
dysbiosis, vaginal trauma and altered pH which may cause BV and increased risk to HIV and 
STI infections 
 
1.2.4 Immunologic and microbiological events associated with mucosal trauma 
1.2.4.1 Sexual trauma 
Some studies have shown that there is a short-term activation of the mucosal immune system 
that is associated with sexual intercourse where deposition of seminal fluid in the FGT has 
been linked to pro-inflammatory cytokine and chemokines expression (Denison et al., 1999, 
Sharkey et al., 2007). The female reproductive tract microbiota is affected by sexual 
intercourse; greater fluctuation in the vaginal flora is associated with frequent intercourse 
(Schwebke et al., 1999a). 
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1.3 Rationale of the study 
Globally, adolescent females are the highest risk group for HIV infection, and vaginal trauma 
potentially increases this risk. The lower reproductive tract of adolescents soon after sexual 
debut may represent a naive reactive state which lacks tolerance to seminal fluid, combined 
with delayed response to pathogens. In this naïve age group of young women, early sexual 
debut and the use of traditional or commercial vaginal inserted products may compound the 
risk of mucosal trauma which may lead to a higher risk of HIV and other infections. This 
study takes advantage of the information on vaginal products already provided by young 
women living in rural KZN where HIV prevalence is high.  It seeks to explore immune 
responsiveness to IVIPs using a PBMC model. Alum and snuff were found to be the products 
that were most commonly used by young women, and these two products were taken further 
to investigate how these IVIPs effect on immune cellular activation and inflammation. The 
ultimate goal is to inform clinical trials and advice adolescent females in developing 
countries on how they can effectively prevent their risk of HIV infection.  
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1.4 Study aims and objectives 
Aim:  
To investigate the in vitro effects of IVIPs exposure on the biomarkers of inflammation and 
cellular activation.   
 
Objectives:   
1. To identify the pH of IVIPs (Snuff, kuber, alum, rose water and savlon) and to evaluate 
the cytotoxicity of the IVIPs by determining their effect on cell viability at different 
dilutions.   
2. To look at the effect of IVIPs (Snuff and alum) on immune cellular activation and 
inflammation using PBMCs in vitro. 
   
Hypothesis:   
IVIPs will lead to cellular immune activation, with subsequently increased inflammation, 
thereby elevating the risk of HIV-1 infection.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Laboratory safety conditions and procedures  
All experiments were carried out inside the biosafety class II hood with appropriate clothing 
and precautions. Table 2.1 shows the general laboratory reagents used to carry out the 
experimentation prepared as recommended. RPMI-1640 media (Invitrogen) was extensively 
used in this project and it was developed at Roswell Park Memorial Institute; it is suitable 
for long term culture of peripheral blood lymphocytes. This media has a pH 8 formulation 
and able to supports a wide variety of cells in suspension if adequately supplemented with 
serum, 10% heat-inactivated foetal bovine serum (FBS, Sigma Aldrich) was added, heated 
to 56°C for 30 minutes to inactivate complement proteins. FBS facilitates cell survival and 
proliferation, and it also increases the viscosity of the media and thus protects the cells from 
mechanical damages during agitation of suspension culture and 6% penicillin/streptomycin 
(Sigma Aldrich) was added to prevent bacterial and fungal contamination of cells.   
 
Table 2. 1. General laboratory reagents 
 
Reagent   Composition   Storage condition   Supplier   
R10  RPMI 1640 MEDIUM, 10% FBS, 
6%penicillin/streptomycin    
4ºC  Prepared in the 
laboratory   
 Foetal Bovine Serum 
FBS   
Blood from fetal calves   -20 ºC  Invitrogen   
Phosphate Buffered 
Saline   
0.138M NaCl,0.0027M KCI (pH 7.2)  RT  Invitrogen   
Trypan blue   C34H28N6O14S4  15-30 ºC  Lonza- Bioscience   
Distilled De-ionized 
water   
No impurities and minerals   RT  Supplied by the 
laboratory  
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2.2 Ethical approval   
The study was conducted at CAPRISA (Centre for the AIDS Programme of Research in 
South Africa) located in Durban, KwaZulu-Natal province, South Africa. Twenty-six black 
African female donors from the urban part of Durban, who are aged between 18 to 30 years 
old and healthy with no known chronic sicknesses donated blood. The eligibility criteria 
were HIV negative status, not pregnant, did not use IVIPs and their marital status was either 
married or single. Women with unknown HIV status, HIV infected individuals, pregnant, 
breastfeeding and taking medication for chronic sicknesses were excluded from the study. 
All participants agreed to sign an informed consent before the commencement of the study. 
Ethical approval for the study was granted by the University of KwaZulu-Natal Biomedical 
Research Ethics Committee (BREC), ref no: BE382/16.  
 
2.3 Selection and preparation of intravaginal insertion products 
Information about some commonly used intravaginal insertion products were discovered at 
Vulindlela Research clinic in Mafakatini, Pietermaritzburg, South Africa through Eleven 
group discussions (“boot camps”). The group discussions were conducted from 2013-2015 
with 495 African females aged 13-24 (Humphries et al., 2019). These products included 
alum (Potassium aluminium sulfate KAl(SO4)2), rose water (distilled water with rose 
flavouring), savlon (chlorhexidine gluconate, cetrimide, n-propyl alcohol benzyl benzoate), 
kuber (Scented Khaini leafy tobacco), and snuff (tobacco, an ammonium carbonate salt, 
preservatives). These products were purchased from street vendors and local shops in 
Durban CBD. Figure 2.1 below shows the format in which selected IVIPs are purchased. 
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Figure 2. 1. Shows the photographs of all IVIPs selected in the format they are mostly 
purchased. Kuber, Alum, and Snuff are solids; Savlon and Rosewater are liquids. 
 
2.3.1 Intravaginal insertion products (IVIPs) processing   
All products were kept at room temperature before use. Solid products of the same kind from 
different containers or packets were transferred into sterile zip bags and mixed to ensure 
uniformity. The concentrations of IVIPs used by women are not known and they vary 
between individuals. Stock solutions of snuff and kuber products were prepared as described 
in Harris et al. (2012) at a concentration of 450 mg/ml, by weighing 18g and adding 40ml of 
phosphate-buffered saline (PBS).  Similarly, alum stock solution was also prepared at a 
concentration of 450 mg/ml to retain dilution ratio of the solid IVIP. In order to completely 
dissolve alum salt, the mixture had to be heated into a water bath at 65ºC for 10-15 minutes 
with constant agitation. Aluminium sulfate and water mixture forms aluminium hydroxide. 
Mixtures were homogenised using a vortex mixer and left at room temperature overnight to 
allow for maximum extraction and filtered using the 0.22µm corning bottle-top vacuum filter 
Solid IVIPs Liquid IVIPs
Snuff
Alum
Kuber
Rosewater Savlon
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systems (Sigma Aldrich). Savlon and rose water were used directly for experimentation as 
they were in liquid form with an unknown concentration of each product; however, sterile 
distilled water (provided by the laboratory) was used as a control for osmotic pressure 
changes in rose water. Table2.2 shows how IVIP dilutions were prepared.  
 
 
Table 2. 2. Shows how IVIPs dilutions were prepared. 
Products  Dilution factor Volume of stock 
solution (450mg/ml) 
or Volume of neat 
liquid product (µl) 
Volume of 
R10 media 
(µl) 
Product 
concentration 
  1 5000 0 450mg/ml 
Solids: (Snuff, 
kuber and Alum) 
 1/5 1000 4000 90 mg/ml 
1/10 500 4500 45 mg/ml 
1/100 50 4950 4.5 mg/ml 
1/1000 5 4995 0.45 mg/ml 
  1 5000 0 100% 
Liquids: (Savlon 
and Rosewater) 
 1/5 1000 4000 20% 
1/10 500 4500 10% 
1/100 50 4950 1% 
1/1000 5 4995 0.1% 
 
2.3.2 pH measurement of IVIPs at different concentrations   
pH used to measure the concentration of hydrogen ions H+ in a solution and therefore 
measure whether the solution is acidic or basic. The pH scale ranges from 0 to14, 7 = neutral, 
<7is acidic and >7 is basic. The lower female genital tract is a very pH-sensitive part of the 
body. The healthy vagina is acidic with a pH below 4.5. This acidic pH keeps the vaginal 
environment free from bacterial pathogens as it is microbicidal. Therefore, it’s crucial to 
measure the pH of the different IVIPs selected, to determine the effect they might impose on 
the vaginal pH 
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         2.3.2.1 Calibration of a pH meter 
The pH meter was calibrated daily before use. It was switched on for at least 30 minutes 
before use to allow adequate time for the pH meter to warm up. The electrode was taken out 
of its storage solution and rinsed with reverse osmosis water (RO) under an empty waste 
beaker. The electrode was gently blotted dry with a paper towel. Three buffers that were pre-
warmed to room temperature were used for calibration. The electrode was immersed into the 
first buffer with a pH of 7; the electrode was left in the buffer until the reading was stable 
then rinsed with RO water. The electrode was then immersed into the second buffer with a 
pH of 4 and left in the buffer until the reading was stable and rinsed with RO water. Then 
the electrode was immersed into the third buffer with a pH of 10 and left in the buffer until 
the reading was stable, and it was rinsed with the RO water. The pH meter calibration status 
was checked, and if the calibration passed, then proceeded to sample pH measurement. 
 
          2.3.2.2 Measurement of pH in selected vaginal products 
Five millilitres of IVIPs (Snuff, Alum, kuber, rose water and savlon) at different dilutions 
(stock,1/5,1/10,1/100 and 1/1000) were added into labelled falcon 15ml conical centrifuge 
tubes and pH was measured using a benchtop pH meter (Mettler-Toledo AG). The pH 
meter’s glass electrode was immersed into each dilution for each IVIPs until the reading was 
stable, and it was recorded. The glass electrode in the pH meter probe was rinsed with RO 
water in between different dilutions and also in between different IVIPs.   
 
2.4 Peripheral Blood Mononuclear Cell (PBMC) processing  
PBMCs are blood cells that can give selective immune system responses, and they are the 
major cells in the immunity of the body (Pourahmad and Salimi, 2015). Therefore, they are 
suitable cell types for characterisation of lymphocytes. The most common method for 
isolating PBMCs from anticoagulant- treated blood specimens is the density gradient 
centrifugation (Bøyum, 1983); this centrifugation uses a density gradient media such as 
histopaque medium. This medium can separate different cell populations through the 
exhibition of unique migration patterns based on cell density, from whole blood each cell 
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population creates a distinct layer resulting into four distinct layers (erythrocytes, 
granulocytes, PBMCs and Plasma) then the PBMCs layer can be isolated. 
 
Blood samples were collected from healthy female donors (to rule out the donors’ 
immunological histories that could influence heterogeneous responses) by venepuncture into 
sterile glass blood collection tubes with acid citrate dextrose (ACD, BD Biosciences). ACD 
is an anti-coagulant for whole blood. Blood samples were processed within 4 hours of 
collection. The Ficoll –density gradient centrifugation was used to obtain the PBMC buffy 
layer. Freshly isolated PBMCs were isolated with reagents described in Table 2.3. To 
improve cell viability, freshly isolated PBMCs were used.   
 
Table 2. 3. Reagents used for PBMC isolation. 
Reagent  Composition Storage 
condition 
Supplier 
Histopaque- 1077  endotoxin tested solution 
of polysucrose and 
sodium diatrizoate, adjusted 
to a density of 1.077g/mL 
2-8ºC Sigma Aldrich 
1XPBS with 2% FBS  PBS + 2% of FBS 4ºC Prepared in the 
laboratory 
FACS wash  PBS + 1% of FBS 4ºC Prepared in the 
laboratory 
 
2.4.1 Peripheral Blood Mononuclear Cell (PBMC) isolation  
Peripheral Blood Mononuclear Cells (PBMCs) were isolated using Histopaque-1077 
medium (Sigma-Aldrich), which enables quick recovery of viable lymphocytes from blood 
and separates cells by density gradient centrifugation. Two ACD tubes of blood per donor 
were spun at 2290 x g for 10 min, and the top layer plasma was discarded. The remaining 
blood was diluted with 1xPBS-2% FBS at RT. Diluted blood was then gently mixed by 
pipetting up and down, and the cells were layered over 12ml of histopaque in a 50 ml 
leucosep tubes (Sigma Aldrich). Cells were spun down at 1753 x g for 30 minutes with no 
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brake. The sample separated after the histopaque spin into four layers the plasma at the top, 
followed by the PBMC interface layer just below this layer there was a histopaque layer 
containing granulocytes and the bottom layer were the erythrocytes. Erythrocytes (red blood 
cells) aggregate together, and these dense cell clusters sediment on the very bottom of the 
tube. Granulocytes are located in the histopaque medium layer, directly above the 
erythrocytes. PBMC layer was found in-between the plasma and the histopaque layer; it was 
white buffy interphase and was collected without disturbing the red blood cells at the bottom 
of the tube. Cells were transferred into a new 50mlleucosep tube and washed with 40ml 
1XPBS-2%FBS at RT. Cells were spun at 2290 x g for 10 minutes, and the supernatant was 
discarded. Cells were re-suspended and mixed with 10 ml of R10 growth media. 
 
2.4.2 Cell counting using trypan blue exclusion method    
To obtain the desired number of cells, it was crucial to first count the total number of live 
cells from the 10ml PBMC/media suspension. Trypan blue staining technique was used to 
count the number of viable mononuclear cells. This staining technique was used to 
distinguish between viable and dead cells selectively. Viable cells have an intact cell 
membrane, and the dye cannot transverse through the membrane (Strober, 2015), viable cells 
appeared colourless. In contrast, dead cells do not have an intact cell membrane. Therefore, 
the stain transverses the membrane, and the cells were stained blue. In each counting 
chamber, two squares were selected from the grid and were used to count the average number 
of cells using the formula provided below (the counting formula was adapted from 
(abcam.com). 
 
A volume of 50µl of the cell suspension was mixed with 50µl of trypan blue (WhiteSci) in 
a 96 well plate and cells were rested in the dye for 2 minutes to allow for optimal staining. 
10µl of the solution was transferred into the counting chambers of Fastread slides (Davis 
Diagnostic Pty Ltd.) and viewed under a light microscope at 400× magnification. Two 
squares were counted in the grid and used to count the average number of cells. Each square 
represents a total volume of 10⁴ cm3, and 1 cm3 is equivalent to 1 ml. Therefore, the total 
number of cells was determined using the following calculation: concentration (cells per ml) 
= average number of cells x 10⁴ x 2 (dilution factor). 
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2.5 PBMC exposure to IVIPs 
2.5.1 Viability testing 
It was previously reported that 80% of the viability of PBMCs is recommended before 
starting experimentation (Glisic‐Milosavljevic et al., 2005), therefore it was crucial to 
determine the optimal times of exposure and optimal dilution that would give the optimum 
viability. When PBMCs were exposed to IVIPs for a longer period >3hours it led to poor 
cell viability, however, at 3hours of IVIP exposure the cell viability improved, therefore 
3hours was chosen as the optimal time for the exposure of IVIPs. One million PBMC 
suspension was added into round bottom falcon tubes (Becton Dickson) in order to have 
enough cells to acquire at least 50 000 events from the lymphocyte population and also to 
compensate for cell loss during fixation. PBMCs were exposed to IVIPs at different dilutions 
(stock, 1in 5, 1in10, 1in100 and 1in1000) including distilled water which was used as a 
control for osmotic pressure changes in rose water. Each IVIP exposure were done in 
triplicates per dilution. 
 
The 1in1000 dilution was the only dilution that had a cell viability of ≥60% from all the 
products used, and therefore it was found to be the optimal dilution for all IVIPs used. 
Thereafter the optimal IVIP dilution was used for PBMCs exposure to evaluate the impact 
of IVIPs on cell activation and inflammation. Snuff and alum were selected to be 
representative products due to financial constraints. Thereafter PBMCs were exposed to the 
optimal dilution of snuff and alum. One million cell suspension was added into round bottom 
falcon tubes (Becton Dickson). Cells were spun at 2290 x g for 10min, the supernatant was 
decanted, and the tubes flicked to re-suspend the cells,1000µl of the (1 in 1000 dilution of 
Snuff and Alum) were added to the labelled tubes and incubated for 3hours at 37ºC in the 
presence of 5% CO2.  
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2.5.2 Experiment controls  
R10 (RPMI 1640, 10% FBS, 6% penicillin/streptomycin) media was used as a negative 
control, which served as a comparison for IVIP treated cells. PHA (Phytohaemagglutinin, 
Sigma) was used as a positive control to ensure that the assays worked and that the cells 
were functional. PHA is extracted from a plant called Phaseolusvulgaris that contains potent 
cell-agglutinating and mitogenic properties. It binds a variety of glycoproteins on the surface 
of T cells and binds the T cell antigen receptor. The monoclonal antibodies in the T cell 
antigen receptor can trigger T cell activation. PHA is a multivalent lectin. Therefore, it does 
not only bind T cell surface glycoproteins, but it also cross-links these cell antigens with 
other T cell surface molecules, therefore, generating an activation signal (Karmańska et al., 
1996).1000µl of the R10 media and 10 µg/ml of PHA were added to the labelled round 
bottom falcon tubes (Becton Dickson) containing 1x10⁶ cells suspension. As in IVIP treated 
cells, cells were stimulated for 3 hours at 37ºC in the presence of 5% CO2.  
 
2.6 Investigation of cellular immune activation using flow cytometry 
The aim of this test was to evaluate the activation status of CD4+ and CD8+ T cells by CD38+ 
and HLA-DR+ activation markers after exposure to IVIPs, T Cell-mediated immune 
responses depend directly on the interaction between T-lymphocytes and the cells bearing 
the antigen. Flow cytometry uses fluorescence to measure the physical and chemical 
characteristics of cells or other particles such as latex beads etc. Fluorescent dyes can 
intercalate cellular components such as DNA or RNA. A fluorescently labelled cell in a 
liquid suspension when passed through a laser becomes excited and moves from its resting 
state to an excited electronic singlet state, and upon returning to its resting state it emits light 
at a higher wavelength, and the duration of this process is quite rapid, and it lasts for 1-10 
nanoseconds (Brown and Wittwer, 2000). A fluorochrome (fluorescent label) when bound 
to a cell component, the fluorescent intensity will represent the amount of that cell 
component. The amount of energy required is different for each fluorophore (fluorescent 
marker). The use of multiple fluorochromes allows detection of several cell properties to be 
measured simultaneously and from a population of fluorescently labelled cells a flow 
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cytometer can sort cells into negative and positive cells of interest and the cells of interest 
can be further analysed based on the conjugated antibodies (Brown and Wittwer, 2000). 
 
2.6.1 Configuration of the flow cytometer 
When designing a flow panel, it is very crucial to have knowledge of the flow cytometer to 
be used. To know how many markers can be included in the panel, it becomes crucial to 
know the configuration of the cytometer and how many lasers the instrument has. The BD 
LSRII Fortessa flow cytometer (BD Bioscience) used has three lasers (blue, violet and red) 
and 12 channels available as shown in figure 2.2. 
 
 
  
Figure 2. 2. Shows the configuration of LSRII flow cytometer channels and lasers (BD Biosciences) 
 
A 7-colour flow panel was used to identify T lymphocyte activation. The unwanted cells 
were identified in the dump channel (Pacific blue), a dump channel was essential for placing 
CD19 because it identifies B cells that are not of interest. A viability dye (live/ dead fixable 
violet dye) conjugated to Pacific blue was essential for reducing the background noise that 
could result from the uptake of antibodies by dead cells that bind non-specifically. Therefore, 
the dump channel Pacific blue served to clean up the analysis by removing contamination in 
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the downstream analysis. T cell lymphocytes can recognise antigens because they are 
tolerant of self-molecules and highly sensitive to non-self-molecules. Studying how T cell 
activates immune responses is essential for understanding immune regulation disorders 
(Wan, 2010).Live T cells (CD3+) were identified by the expression of T cell membrane 
receptors CD4 and CD8 antigens with the functions of T helper and cytotoxic T cells, 
respectively. The activation of these cell subsets was assessed with CD38+, HLA-DR+ 
activation markers and also through the dual expression of these markers (CD38+HLA-DR+). 
To identify HIV target cells and HIV co-receptor expression CCR5+ was used as a marker.  
 
2.6.2 Selection of markers  
To determine the in-vitro effects of IVIPs on immune activation, a number of important 
markers needed to be included. Incorporating a viability marker (Vivid) was crucial for 
discrimination of viable cells from non-viable cells as PBMCs are most likely to bind 
antibodies non-specifically. To exclude B-cells CD19 antibody was included, and that 
improved specificity and sensitivity of the assay. Since this study was investigating the T-
lymphocytes activation, CD3, CD4, and CD8 markers were included because they 
differentiate T lymphocytes' lineage. At the activation of T lymphocytes was determined by 
looking at the CD38 and HLA-DR activation markers. Chemokine receptor CCR5 an HIV 
co-receptor was included for identifying the HIV target cells. 
 
2.6.3 Optimization of the flow cytometry panel 
2.6.3.1 Selection of fluorochromes 
In polychromatic flow cytometry, there is the variability of fluorochromes that can be 
chosen; however, not all markers are available commercially on all fluorochromes. 
Therefore, antibody selection is a very crucial step when constructing a panel. An ideal panel 
would include bright antibodies which give the best separation, therefore, limiting spectral 
overlap. Fluorochromes with identical excitation and emission properties but different 
spillover characteristics were not used simultaneously in this panel. Details of the chosen 
flow cytometry marker are shown in table 2.4 below, the viability marker fluoresces in the 
Pacific blue channel. Therefore, CD19 and Dead cells were placed on the same channel 
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(Pacific blue channel), as they both needed to be excluded. CD3 was placed in the APC-H7 
channel, CD4 was placed in the PECy5.5 channel, CD8 was placed in the BV711 channel, 
HLA-DR was placed in the Alexa-fluor-700 channel, CD38 was placed in the PE-Cy7 
channel, and CCR5 was placed in the APC channel. 
 
Table 2. 4. Details of the chosen flow cytometry panel 
Reagent  Channel   Storage   Supplier   
Live /Dead fixable violet 
dye  
Pacific blue   -20ºC  Molecular probes  
CD19  Pacific blue   4ºC  Invitrogen  
CD3  APC-H7  4ºC  BD  
CD4  PECy5.5  4ºC  Invitrogen  
CD8  Bv711  4ºC  Biolegend   
CD38  PE-Cy7  4ºC  eBiosciences   
HLA-DR  Alexa flour 700  4ºC  Biolegend   
CCR5  APC   4ºC  BD  
 
2.6.3.2 Staining non-viable cells using live/dead fixable violet dead cell stain (“Vivid”) 
The vivid dye is a reactive amine dye, and it is a viability dye. This dye is suitable for 
identifying dead cells in samples by permeating cell membranes of dead cells and reacting 
with free amines in the cell’s cytoplasm. However, this dye is excluded by live cells because 
it cannot penetrate their intact cell membranes. When cells are fixed, the dye is only 
associated with the dead cells, and they can be identified by the fluorescence emitted when 
the dye is excited by lasers (Perfetto et al., 2010).  
 
The stock concentration of Vivid dye was prepared with 25µg of an amine-reactive dye and 
DMSO. Lyophilized DMSO that comes with a kit was thawed in a 37ºC water bath until 
completely thawed, 50µl of DMSO was added into a vial of lyophilised dye.1µL, the 
optimum volume (after titration) of 500µg/ml stock was added to 39µl of distilled water, and 
then 1µl of this concentration was added into 49µl of PBS, resulting into a working 
concentration. This working concentration was used to make a master mix, and 50µl of the 
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master mix was added to 150µl of PBS containing cells and incubated at RT for 20 min in 
the dark. Cells were washed twice with PBS and stained with fluorochrome-conjugated 
antibodies. Table 2.5 below shows the list of the reagents used to stain surface markers. 
 
 
 
Table 2. 5. List of reagents used to stain surface markers 
Reagents   Storage conditions  Supplier   
Dulbecco’s PBS  4ºC  Sigma Aldrich   
10X CellFix   4ºC  BD  
Anti-mouse compensation 
beads  
4ºC  BD  
 
2.6.4 Antibody staining of IVIP exposed PBMCs  
 
Cells were suspended after the 3-hour incubation by gentle shaking of the FACS tubes and 
settling for 3 min, spun at 2290 x g for 10min and transferred the supernatants into Eppendorf 
tubes (Sigma Aldrich). The supernatants were stored at -80 ºC to be used for the 
measurement of genital tract cytokines. One millilitre of FACS wash was added into the 
tubes and spun at 2290 x g for 10min, and the supernatant was discarded. The cells were 
washed with 150µl of PBS and 50µl of the vivid master mix was added to the tubes and 
suspended with a pipette. The tubes were covered with foil and incubated for 30min in the 
dark at 37ºC. FACS wash (200µl) was added into each tube and centrifuged at 800 x g for 
5min at 4 ºC. Fifty microlitres (50µl) of the chemokine master mix Allophycocyanin   
labelled anti-CCR5 and FACS wash was added and incubated for 30 minutes in the dark at 
37ºC because it stains optimally in this temperature. Cells were washed twice with 200µl of 
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PBS-1, and 50µl of the surface antibody master mix (Allophycocyanin-H7 labelled anti-
CD3, phycoerythrin cyanine 5.5–labelled anti-CD4, Brilliant Violet 711–labelled anti-CD8, 
phycoerythrin cyanine 7-labeled anti-CD38, Alexa flour 700-labelled anti-HLA-DR, Pacific 
blue-labelled anti-CD19 and Live/dead was added, re-suspended and incubated in the dark 
for 20min at RT for 20min. Cells were washed twice with 200µl of FACS wash. 150µl of 
1X cellFix (Becton Dickinson) was added, re-suspended, wrapped with foil and acquired in 
a BD LSRII Fortesa flow cytometer (BD Biosciences). Table 2.6 below shows how the 
master mix preparation was made for one reaction. 
 
                          
Table 2. 6. Shows master mix preparation for one reaction and the pre-titrated volumes 
  X1 reaction   
Chemokine mastermix stained at 37ºC  
CCR5 APC   5 µl  
PBS-1  45 µl  
    
Surface antibody master mix stained at RT  
CD19 Pac blue   2µl  
CD3 APC-H7  1.5µl  
CD4 PE-Cy5.5  0.5µl  
CD8 BV711  0.5µl  
CD38 PE-Cy7  1µl  
HLA-DR Alexa flour 700  2µl  
FACS WASH   42.5 µl         
  
2.6.5 Compensation controls  
Each fluorochrome in the selected panel has an excitation and emission spectra when the 
fluorescence from the spectra overlap more than one fluorochrome can be detected in a single 
channel. A range of light wavelengths that add energy to a fluorochrome is the excitation 
spectrum, and it causes the fluorochrome to emit light in another range of wavelengths 
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referred to as emission spectrum which is shown in the figure. Therefore, compensation is 
used to correct for spectral overlap by removing the signal spillover from one fluorochrome 
into any other parameter, ensuring that fluorescence detected from a particular detector is 
from a specific channel only.  Compensation controls are a single colour controls stained 
with one fluorophore per control using the exact test sample conditions (Bagwell and Adams, 
1993). 
 
Compensation beads (BD Bioscience) were stained with individual fluorochrome-
conjugated antibodies for use as single-colour compensation controls. Briefly, 7 FACS tubes 
were labelled with each fluorochrome and one negative tube. The compensation beads were 
vortexed and one drop placed into each tube, and appropriate volume of each antibody 
(according to the antibody titrations) was added and centrifuged at 800 x g for 3min at 4ºC. 
Beads that react with mouse antibodies were used for all antibodies. The tubes were vortexed 
and re-suspended, incubated for 20 min in the dark at RT. PBS (1ml) was added to each tube 
and centrifuged at 800 x g for 3 min at 4ºC. The supernatants were decanted, and 150µl of 
1X cell fix (1ml of 10X cell fix added to 9ml DD water) was added to each tube and vortexed 
briefly.  
 
2.6.5.1 Preparation of Rainbow beads  
The intensity of the fluorescence is dependent on the functionality of the flow cytometer 
machine, including laser power, alignment, temperature, and optical density. The first step 
when setting up the flow experiment is adjusting the sensitivity of the detectors to optimise 
instrument performance for the run. However, these voltages are not always optimal for the 
next assay run. Therefore, rainbow beads are acquired under optimised instrument settings 
to generate a set of target values that would reflect the instrument sensitivity (Holmes K, 
2001). Rainbow beads are fluorescent particles that emit as a single peak in each instrument 
channel, therefore to set-up the instrument these beads are acquired first, and the voltages 
are adjusted until the bead peak hits the target values (Maecker and Trotter, 2009). Three 
hundred microliters of PBS-1 were added to the tube labelled "Rainbow", and after that the 
rainbow beads were vortexed, one drop was added to the tube. The mixture was vortexed 
and stored on ice.  
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2.6.5.2 Fluorescence minus one control (FMO)  
To properly identify the spread of the fluorochromes into the channel of interest, and FMO 
control is used. FMOs are important because they help determine where the gates should be 
placed in a multicolour panel. To accurately discriminate between positive and negative 
signals, FMO controls are mandatory (Roederer, 2001). FACS tubes were labelled with each 
fluorochrome (Allophycocyanin-H7 labelled anti-CD3, phycoerythrin cyanine 5.5–labelled 
anti-CD4, Brilliant Violet 711–labelled anti-CD8, phycoerythrin cyanine 7-labeled anti-
CD38, Alexa flour 700-labelled anti-HLA-DR, Pacific blue-labelled - Live/dead). One 
million PBMCs suspensions were added into round bottom falcon tubes (Becton Dickson). 
Cells were spun at 2290 x g for 10min, the supernatant was decanted, and the tubes flicked 
to re-suspend the cells,1000µl of the (1 in 1000dilution of Snuff and Alum) were added to 
the labelled tubes and incubated for 3hours at 37ºC in the presence of 5% CO2.  An 
appropriate volume of each antibody (according to the antibody titrations) was added minus 
one labelled in the tube and centrifuged at 800 x g for 3min at 4ºC. The tubes were vortexed 
and re-suspended, incubated for 20 min in the dark at RT. PBS (1ml) was added to each tube 
and centrifuged at 800 x g for 3 min at 4ºC. The supernatants were decanted, and 150µl of 
1X cell fix (1ml of 10X cell fix added to 9ml DD water) was added to each tube and vortexed 
briefly.   
 
          2.6.6 Data acquisition  
After staining, cells were stored at 4ºC in the dark and acquired within 24h. PBMC samples 
were acquired on a BD LSRII Fortessa flow cytometer (BD Biosciences), Flow cytometry 
analysis was performed using FlowJo software version 10 (Tree star) with FacsDiva 
software. The number of events collected was 500000- 1000000.  
 
       2.6.7 Data QC and Management  
Time gates used to exclude fluorescence shifts that may occur during acquisition were used. 
N by N plots were conducted per run to generate the correct compensation matrix plot and 
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adjustments done after plot acquisition. The compensation matrix was applied to 
compensation controls for the trace of Tandem dye degradation.  
 
2.7 Investigation of biomarkers of inflammation using Bio-Plex  
Cell proteins such as Cytokines and chemokines are expressed by all cell types, including 
epithelial and endothelial cells, and they are also immunologically expressed. These proteins 
can interact with specific receptors on target cells to facilitate physiological responses such 
as haematopoiesis, growth, immunity, and inflammation, and their dysregulation is 
associated with pathological conditions. Detection of the cytokine profile allows 
determination of the type of preferentially activated immune responses. Using the 
multiplexed fluorescent bead-based detection assay such as Bio-Plex allows for the detection 
of multiple cellular proteins simultaneously. A schematic representation of Bio-Plex assay 
principle is shown in figure 2.3. 
 
The aim of this test was to evaluate the PBMC immune response to IVIP exposure measured 
by cytokine and chemokine production. Supernatants from PBMCs of n=12 individuals 
(collected after 3 hours of exposure) stored at -80°C freezer were thawed and concentration 
of all cytokines and chemokines (interleukin (IL)-1β, IL-6,tumour necrosis factor (TNF)–α 
and granulocyte-macrophage colony-stimulating factor (GM6, and granulocyte-macrophage 
colony-stimulating factor (GM–CSF); chemokines (interleukin (IL)-8,interferon gamma-
induced protein (IP)-10, monocyte chemotactic protein (MCP)-1, macrophage inflammatory 
protein (MIP)–1α and macrophage inflammatory protein (MIP)-1β); Hematopoietic 
cytokines (interleukin (IL)-7) and regulatory cytokines (interleukin (IL)-10) were measured 
using Bio-Plex Pro Human Cytokine kits (Bio-Rad Laboratories) and a Bio-Plex MagPix 
Array Reader (Bio-Rad Laboratories) according to the manufacture’s protocol.  All samples 
had the same freeze-thaw history at the time of testing. Bio-Plex assay kit reagents were 
brought to room temperature excluding the detection antibody, detection antibody diluent, 
streptavidin-phycoerythrin and magnetic beads were kept in a 4ºC fridge. The sensitivity of 
the Bio-Plex assay kit ranged between 0.2 and 45.2pg/ml for each of the 11 cytokines 
measured 
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The Bio-Plex multiplex system uses fluorescently labelled beads each colour coded to 
discriminate the individual tests in a multiplex suspension following a stepwise fashion as 
demonstrated in the figure. Capture antibodies directed to the desired biomarker are 
covalently coupled to the magnetic beads. The biomarker of interest in a sample detects the 
reaction of the beads in the sample. The unbound proteins are removed by a series of washes 
after and a biotinylated detection antibody is added to create a sandwich complex. The 
addition of streptavidin-phycoerythrin (fluorescent indicator) conjugate forms the final 
detection complex.   
 
 
 
Figure 2. 3. Schematic representation of a bio-Plex assay principle (the figure was adapted 
from Bio-Rad.com). Step one is the dispensation of capture antibodies, and step two is the 
addition of the sample, step three is the addition of the detection antibody, step four is the 
addition of the reporter dye and step five fluorescent sorting and data reduction. This 
experiment aimed to investigate the inflammatory biomarkers in PBMC culture supernatants 
after exposure to IVIPs. 
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2.7.1 Bio-Plex plate preparation 
 
Fifty microliters of thawed supernatant samples were placed in wells of the v-bottom 96 well 
plates (Costar) master plate, to limit the variability of sample exposure as a result of magnetic 
beads. Two 27-Plex Pro plates were prepared. Each plate included six duplicated supernatant 
samples as controls for reproducibility measurements within a plate and thirty supernatant 
samples each duplicated to investigate the reproducibility of cytokine measurements across 
plates. A representative plate layout is shown in table 2.7 below.       
 
 
Table 2. 7. Representative plate layout showing the plate design. 
         
 
1 2 3 4 5 6 7 8 9 10 11 12
A S1 S1 S9 S9 5 5 13 13 21 21 29 29
Snuff_2018/11/12_R10 Snuff_2018/11/12_R10 Snuff_2018/11/13_PHA Snuff_2018/11/13_PHA Snuff_2018/11/14_1/1000 Snuff_2018/11/14_1/1000 Snuff_2018/12/14_R10 Snuff_2018/12/14_R10
B S2 S2 S10 S10 6 6 14 14 22 22 30 30
Snuff_2018/11/12_1/1000 Snuff_2018/11/12_1/1000 Snuff_2018/11/13_R10 Snuff_2018/11/13_R10 Snuff_2018/11/14_PHA Snuff_2018/11/14_PHA Snuff_2018/12/14_1/1000 Snuff_2018/12/14_1/1000
C S3 S3 Blank Blank 7 7 15 15 23 23 31s 31s
Snuff_2018/11/13_PHA Snuff_2018/11/13_PHA Snuff_2018/11/13_1/1000 Snuff_2018/11/13_1/1000 Snuff_2018/11/14_R10 Snuff_2018/11/14_R10 Snuff_2018/12/19_PHA Snuff_2018/12/19_PHA
D S4 S4 Cntrl Cntrl 8 8 16 16 24 24 32s 32s
Snuff_2018/11/13_R10 Snuff_2018/11/13_R10 Snuff_2018/11/13_PHA Snuff_2018/11/13_PHA Snuff_2018/11/14_1/1000 Snuff_2018/11/14_1/1000 Snuff_2018/12/19_R10 Snuff_2018/12/19_R10
E S5 S5 1 1 9 9 17 17 25 25 33s 33s
Snuff_2018/11/12_PHA Snuff_2018/11/12_PHA Snuff_2018/11/13_1/1000 Snuff_2018/11/13_1/1000 Snuff_2018/11/13_R10 Snuff_2018/11/13_R10 Snuff_2018/11/14_PHA Snuff_2018/11/14_PHA Snuff_2018/12/19_1/1000 Snuff_2018/12/19_1/1000
F S6 S6 2 2 10 10 18 18 26 26 34s 34s
Snuff_2018/11/12_R10 Snuff_2018/11/12_R10 Snuff_2018/11/13_PHA Snuff_2018/11/13_PHA Snuff_2018/11/13_1/1000 Snuff_2018/11/13_1/1000 Snuff_2018/11/14_R10 Snuff_2018/11/14_R10 Snuff_2018/12/19_PHA Snuff_2018/12/19_PHA
G S7 S7 3 3 11 11 19 19 27 27 35s 35s
Snuff_2018/11/12_1/1000 Snuff_2018/11/12_1/1000 Snuff_2018/11/13_R10 Snuff_2018/11/13_R10 Snuff_2018/11/13_PHA Snuff_2018/11/13_PHA Snuff_2018/11/14_1/1000 Snuff_2018/11/14_1/1000 Snuff_2018/12/19_R10 Snuff_2018/12/19_R10
H S8 S8 4 4 12 12 20 20 28 28 36s 36s
Snuff_2018/11/12_PHA Snuff_2018/11/12_PHA Snuff_2018/11/13_1/1000 Snuff_2018/11/13_1/1000 Snuff_2018/11/14_R10 Snuff_2018/11/14_R10 Snuff_2018/11/14_PHA Snuff_2018/11/14_PHA Snuff_2018/12/19_1/1000 Snuff_2018/12/19_1/1000
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2.7.1.1 Beads Preparation and Validation 
Anti-cytokine beads (10X) stock solution was mixed by vortexed at medium speed and 
sonicated for the 20s. A 10-fold working dilution was prepared by adding 575 µl of beads 
into 5175 µl of the Bio-Plex assay Buffer to make a total volume of 5750 µl of the bead 
working solution and covered with foil for protection from light. Beads working solution 
was vortexed and 25µl of solution added into each well. Vacuum filter washed (2X) with 
100 µl of Bio-Plex Wash Buffer at the Bio-Plex Pro II (BIO-RAD) automated washing 
station. A 50 µl vortexed standard added into the appropriate well, blanks were also included. 
Subsequently, 50µl of vortexed samples were added to each corresponding well. Plate 
covered with adhesive sealer and blotted at the bottom then covered with a foil, incubated 
for 30 minutes at room temperature shaking at a speed of 1082 x g for 30 seconds and 
reduced to 80 x g for the remaining incubation time.    
 
2.7.1.2 Preparation of detection antibody   
Multiplex antibody detection solution (10X) provided in a kit was gently vortexed, and 
working stock dilution was prepared with Bio-Plex Detection Antibody diluent. Plate sealer 
was removed, and filter washed (3X) with 100 µl of Bio-Plex Wash Buffer at the Bio-Plex 
Pro II (BIO-RAD) automated washing station. Afterwards, 25 µl gently vortexed detection 
antibody added into each well of 96 well plates. Plate covered with plastic adhesive sealer 
and blotted at the bottom then covered with a foil, incubated for 30 minutes at room 
temperature shaking at a speed of 1082 x g for 30 seconds and reduced to 80 x g for the 
remaining incubation time.  
 
2.7.1.3 Preparation of Streptavidin-PE  
Vigorously vortexed Streptavidin stock solution PE (100X) stock solution was used to 
prepare 100-fold diluted working dilution in the Bio-Plex assay buffer. Plate sealer was 
removed, and filter washed 3X with 100 ml of Bio-Plex wash buffer. Subsequently, 50 ml 
of vortexed streptavidin-PE working solution added in each well. The plates were covered 
with plastic adhesive sealer and blotted at the bottom then covered with a foil, incubated for 
30 minutes at room temperature and left in a mechanical shaker at a shaking speed of 1082 
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x g for 30 seconds and reduced to 80 x g for the remaining incubation time. The washing 
step with a Bio-Plex wash buffer was repeated three times at the Bio-Plex Pro II (BIO-RAD) 
automated washing station. Beads were re-suspended in each well with 125 ml of Bio-Plex 
assay buffer.  
2.7.1.3 Standard preparation  
Five hundred microliters of the standard diluent were added into lyophilised standard and 
vortexed for 4s before being incubated on ice for 30min. Polypropylene tubes (BD) were 
used for the standard’s serial dilutions, 72µl was added to the first tube, and 150µl of the 
standard diluent was added subsequently to the other tubes until the tenth standard tube and 
incubated. The reconstituted standard was vortexed and 1:4 serial dilutions performed by 
transferring 50µl of standard one into standard two with 150µl of the standard diluent and 
50µl was added subsequently between tubes until tube S10. 
 
2.7.2 Data acquisition  
Hundred and twenty-five microlitres of the assay buffer were added into each well for the 
data acquisition using the Bio-Plex MAGPIX MultiPlex Reader (Bio-Rad). The plates were 
covered with a plastic adhesive plate sealer, and bottom blotted and shook at a speed of 646 
x g for 30 min. The sealer was removed, and the plate read.  
 
 2.8 Statistical analysis 
Statistical analyses were performed using GraphPad version 7 and Wilcoxon matched-pairs 
signed-rank test was used for comparing two matched samples. All cytokine concentrations 
were log10 transformed to achieve normality. The data from different donors were tested for 
normality using Shapiro-wilk normality test. The percentage coefficient of variation (% 
CVs) of the inter-plate and intra-plate were analysed using descriptive statistics reported as 
medians and interquartile range. Statistical significance was referred to as a p-value less than 
or equal to 0.05, and it was presented by the asterisk rating system (P < 0.05 *, P < 0.01 ** 
and P< 0.001***). Unsupervised hierarchical clustering was performed using R version 
3.6.0. Flow cytometry data were analysed in FlowJo version10 (Tree star) and Excel 
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(Microsoft) prior to statistical testing. Multiplex data was collected using Bio-Plex Manager 
software version 6 (Bio-Rad), and a five-parameter logistic (5PL) regression formula was 
used to calculate sample concentrations from the standard curves. 
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CHAPTER 3: RESULTS 
3.1 IVIP pH measurements at different dilutions  
The female genital tract is a pH sensitive part of the body. A normal vaginal pH level is 
(3.8-4.5) and an introduction of a foreign product in the vagina can alter the normal vaginal 
pH, therefore we measured the pH of all the IVIPs that were selected at different dilutions 
and the results are shown in table 3.1 
 
Table 3. 1. Shows the pH profile of intravaginal insertion products (IVIPs) at different 
dilutions. 
 
Dilutions Alum Snuff Kuber Rose 
water 
Savlon 
Stock/Neat 2.62 9.11 8.21 4.21 6.00 
1/5 3.32 9.32 8.19 7.29 7.37 
1/10 3.52 9.22 7.85 7.36 7.39 
1/100 5.44 8.92 7.66 7.41 7.42 
1/1000 7.23 8.20 7.74 7.42 7.44 
R10 media 7.43 
 
 
 
Alum stock solution and undiluted rose water solution are strongly acidic (pH 2.62 and 
4.21, respectively) and were buffered with the addition of R10 media to be weakly basic. 
Snuff and kuber stock solutions are basic (pH 9.11 and 8.21, respectively), and the addition 
of R10 media does not seem to have a distinctive effect on the pH. The undiluted savlon 
solution is weakly acidic (pH 6.0), and it was buffered with the addition of the R10 to be 
weakly basic. The R10 medium used for diluting IVIPs has a weak basic pH of 7.43  
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3.2 Optimal IVIP dilution  
A challenging factor with IVIPs exposure was not having a standard concentration for each 
product because IVIPs preparation varies according to individuals. Therefore, a range of 
IVIP dilutions (1/5, 1/10, 1/100 and 1/1000) was made from the 450 mg/ml stock (alum, 
snuff, and kuber) or neat (rose water and savlon) IVIPs. This experiment aimed to 
determine the product dilution that would give the optimal viability after cell exposure to 
3 hours at 37°C, in the presence of 5% CO2. Figure 3.1 shows the percentage of T cells 
from the peripheral blood identified using the expression of CD3 after exposure to different 
IVIPs dilutions. Blood was drawn from four different donors who were kept constant 
between IVIPs. 
              
  
Figure 3. 1. Shows cell viability expression on peripheral T lymphocytes stained with Vivid 
viability marker after stimulation with R10 media and being exposed to 450 mg/ml stock 
solution (snuff, kuber and alum), neat (savlon, rose water and distilled water), 1/5, 1/10, 1/100 
and 1/1000 dilutions of snuff, kuber, alum, savlon, rose water and distilled water. Mean data 
of 4 donors is represented and error bars indicate the standard deviation. 
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CD3+ Lymphocytes isolated from PBMCs exposed to IVIPs (alum, snuff, kuber, savlon, 
rose water and distilled water) for 3 hours and stained with the optimal volume (1.5µl) of 
anti-CD3, APC-H7. PBMCs from 4 different donors were used for each condition (R10 
media, stock/neat, 1/5, 1/10, 1/100, 1/1000) per IVIP and the same donors were used for 
each IVIP testing (Figure 3.1). The percentages shown correspond to CD3+ cells (mean ± 
SD).  
 
Alum exposure results in a high percentage of cell death. The viability of CD3+ T cells 
after a 3-hour alum exposure ranged from 2 to 70%, for stock, 1/5, 1/10, 1/100 and 1/1000, 
the mean viability is 2%, 5%, 7%, 22%, and 70%, respectively. Snuff exposure results in a 
low percentage of cell death. The viability of CD3+ T cells after a 3-hour exposure to snuff 
ranged from 2 to 50%. For stock, 1/5, 1/10, 1/100 and 1/1000, the mean viability is 2%, 
30%, 35%, 40% and 50%, respectively. Cell exposure to kuber results in a low percentage 
of cell death. The viability of CD3+ T cells after a 3-hour kuber exposure ranged from 2 to 
55%. For stock, 1/5, 1/10, 1/100 and 1/1000, the mean viability is 2%, 25%, 30%, 40% and 
55%, respectively (Figure 3.1).  
 
Cells exposure to savlon results in a high percentage of cell death. The viability of CD3+ 
T cells after a 3-hour savlon exposure ranged from 1 to 40%. For neat, 1/5, 1/10, 1/100 and 
1/1000, the mean viability is 1%, 1.5%, 2%, 2.5% and 40%, respectively. Cell exposure to 
rose water results in a low percentage of cell death. The viability of CD3+ T cells after a 3 
hour rose water exposure ranged from 40% to 60%. For neat, 1/5, 1/10, 1/100 and 1/1000, 
the mean viability was 40%, 55%, 56%, 57% and 60%, respectively. Exposure to distilled 
water results in a very low percentage of cell death; distilled water was used as a control 
for rosewater stimulation. To check if the results obtained from rose water stimulation were 
because of water or because of the rose extracts because water diffusion by osmosis across 
the cell membrane could result in swelling of the cells and bursting causing the cells to die. 
The viability of CD3+ T cells after a 3 hour distilled water stimulation ranged from 75% 
to 90%. For neat, 1/5, 1/10, 1/100 and 1/1000, the mean viability is 75%, 85%, 86%, 88% 
and 90%, respectively (Figure 3.1).  Stimulation of cells for 24 hours led to significantly 
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reduced cell viability (results not shown), therefore, the rest of the stimulations described 
in this thesis were done for the duration of 3 hours. 
  
Alum and snuff were selected as representative products to be used for further experiments 
due to the following reasons: (i) they were one of the most commonly used IVIPs compared 
to others (Humphries et al., 2019) (ii) and also due to budget constraints, only two products 
could be tested extensively.  
3.3 Optimal titer of all antibodies  
To ensure that all antibodies are used at a volume that provides the best separation of 
negative and positive populations, it is important that titrations are performed on all 
antibodies. Mean fluorescent intensity (MFI) graph is the measure of a cell fluorescence 
distribution level and it was quantified using the median for the positive and the negative 
populations, the titre is chosen at the lowest volume where saturation is reached. The signal 
to noise ratio graph is also used to determine the optimal titre, the ratio is calculated by 
dividing the positive population (the signal) by the negative population (the noise, and the 
optimal titre is the highest ratio value. Table 3.2 shows the optimal titre for all antibodies 
used in this experiment. All titrations were stained with Vivid to avoid an incorrect reading 
that could result from dead cells accumulating in the antibody.  
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Table 3. 2. Shows the optimum volume of all the antibodies in the panel. 
Marker  Channel Optimum titre (µl) 
Live/dead Vivid Pacific blue  1 
CD19  Pacific blue 2 
CD3 APC-H7 1.5 
CD4 PE-Cy5.5 0.5 
CD8 BV711 0.5 
CD38 PE-Cy7 1 
HLA-DR Alexa fluor 700 2 
CCR-5 APC 5 
 
3.3.1 Titration of viability dye Vivid 
Vivid as the dead cell marker also required titration. Different titration volumes (1µl, 2µl, 
and 5µl) were used. The ideal concentration should give a clear separation between the 
negative and positive populations. Figure 3.2 A demonstrates the titration of vivid, the 
negative population represents the live cells, and the positive population represents dead 
cells; figure 3.2 B shows how the optimal titre was able to separate between the negative and 
positive populations in a flow plot of vivid against CD3 and figure 3.2 C shows the positive 
signal relative to the background in the MFI and signal to noise ratio graphs. The chosen 
volume of 1 µl was based on the maximum separation of the negative and positive 
populations and also based on minimal spillover. The volume of 1µl was acceptable because 
when considering reactive amine dye, the lowest background signal is more important than 
the absolute positive signal. Vivid staining was performed before surface staining to prevent 
it from attaching to the antibodies’ amine groups. 
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Figure 3.2. Representative titration of a reactive amine dye Vivid- Pacific used for staining 
dead cells. Unstimulated PBMC cells were stained with dilutions of vivid dye (1, 2 and 5 µl). 
After vivid staining was complete, cells were stained with anti-CD3 using standard staining 
procedures. (A) Shows flow plots showing the separation of the positive and negative 
populations from the three vivid dye dilutions, the value at the top right corner of each flow 
plots represents the volume of vivid added. (B) Shows a representative flow plot of the 
working dilution of 1 µl of vivid and anti-CD3. (C) Illustrates the differences in the positive 
signal relative to the background staining, the MFI graph CD19+(red) CD19- (blue), signal 
to noise ratio = positive MFI / negative MFI, the separation is acceptable at the lower dilution 
1 µl which also gave a lower background. 
 
3.3.2 Titration of surface markers 
The next step after viability staining is surface marker staining, PBMCs were stained as 
described in chapter 2. As an example titration of APC-CCR5 antibody is shown in figure 
3.3, at the lower concentration (0.30µl) of APC-CCR5 no distinct positive population could 
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be identified. The MFI graph revealed that 5µl of this antibody was the optimum to use in 
the assays 
 
Figure 3.3. Representative titration of APC-CCR5. (A) Flow plots showing the separation of 
the positive and negative populations from the five APC-CCR5 dilutions 0, 0.30, 0.60, 1.25, 
2.50 and 5 µl indicated at the top right corner of each flow plots. (B) Illustrates the differences 
in the positive signal relative to the background staining, the MFI graph CCR5+ (red) and 
CCR5- (blue) (C) signal to noise ratio = positive MFI / negative MFI, the separation is 
acceptable at the dilution 5µl. 
3.3 Gating strategy  
In flow cytometry analysis gating is one of the fundamental steps because gates are placed 
upon the cell populations of interest to investigate and quantify these populations. The first 
step in the gating strategy used included the time plot to remove any inconsistencies that 
might have occurred during acquisition, by gating where there are no interferences. Gating 
on forward scatter- height against forward scatter- area ensures that the fluorescence detected 
is from single cells by excluding the duplets. When distinguishing cell populations, the first 
step is based on forward and side scatters properties, forward and side scatter give an 
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estimation of the size, the granularity of the cells, and they help to distinguish cell types. Our 
cell type of interest was lymphocytes. Plotting the dump channel (pacific blue) against CD3 
APC-H7 ensured the exclusion of cell debris, dead cells, and monocytes by gating on the 
positive CD3 lymphocyte population to further examine T cells. The CD3+ T cells were 
further identified and gated by the expression of CD4+ and CD8+ T cells subsets, the relative 
expression of CD38+, HLA-DR+ activation markers, and CCR5+ the HIV co-receptor (Figure 
3.4). 
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Figure 3.4. Shows the sequential gating strategy applied for this analysis. The first flow plot 
shows the measurement of forward scatter height and time to remove any inconsistencies in 
the flow of cells to ensure a higher quality of data. The second plot shows the measurement 
of forward scatter height and forward scatter area to remove clumps/ duplets and determine 
the single cells inside a diagonal gate. From the singlets, the analyses were narrowed by 
plotting side scatter area, and forward area scatter for identifying lymphocytes (inside an 
oval gate) while excluding the B cells, monocytes, granulocytes, and dead cells. From the 
lymphocytes gate, viability gate is set up by gating live CD3+ T cells by plotting dump channel 
using Pacific blue (dead cells, CD14 and CD19) with CD3+ T cells. Live CD3+ T cells were 
further subdivided into CD4+, and CD8+ T cells and these were subsequently analysed for 
activation markers of interest HLA-DR+ and CD38+. 
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3.4 Flow cytometry controls  
To be certain that the results were not influenced by the background variation and non-
specific effects, the following controls were applied. 
 
3.4.1 Fluorescent minus one (FMO) controls 
FMO control ensures proper gate positioning, taking into consideration the fluorescence 
spread. Ensuring that there were no spillovers, each FMO was plotted against all the other 
fluorochromes in the panel. Representative plots for CD38-PE-Cy7 FMO is shown in Figure 
3.5 All FMO controls for all the fluorochromes in the panel are shown in Figure3.6. 
 
 
Figure 3. 5. Flow cytometry plots showing an application of an FMO control to determine the 
fluorescence spread. The FMO control shows the fluorescence spread into the PE-Cy7 
channel compared to an unstained control. The red dotted line represents the FMO gating 
boundary compared to the unstained boundary in purple. 
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Figure 3. 6. Shows FMO’s from CD4+ and CD8+ T cells for all fluorochromes in the panel. 
(A) shows the percentage of CD4+ T cells for all the fluorochromes in each FMO channel for 
CD38, CCR5, and HLA-DR. (B) shows the percentage of CD8+ T cells for all the 
fluorochromes in the Each FMO channel for CD38, CCR5, and HLA-DR. There is no 
fluorescent spillover into any of the channels in the panel, for both CD4+ and CD8+ T cells. 
All cells were gated from CD3+T cells, percentages of each cell subset were used. 
  
3.4.2 Unstained control 
In order to determine the negative population, the level of background auto-fluorescence and 
to set voltages correctly, an unstained control was acquired, and from the unstained 
population, the level of background fluorescence and auto-fluorescence were determined. 
After that, the voltages and negative gates were set appropriately. Figure 3.7 shows the 
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negative and positive cell populations, therefore, the position where the negative gate should 
be placed.  
  
 
 
Figure 3. 7. Flow cytometry plots showing (A) unstained lymphocytes are used to set the 
negative population, allowing (B) the positive population stained with CD4 PE-Cy5.5 and 
CD8 BV711to be visualised. 
  
3.4.3 Compensation Controls 
Compensation controls were included as previously discussed in Section 2.5.3. When using 
multiple fluorophores, a compensation control is stained with a single antibody, and single 
stains are essential for determining the levels of compensation because they reveal the level 
of spectral overlap between different fluorophores, and compensate for this overlap. 
Determining which colour to match to which antibody in the reagent panel is the most critical 
factor because some fluorophores are brightly expressed while others are dimly expressed 
and reagents’ signals optically interfere with each other. The emission spectra of the 
fluorochromes in the panel were viewed using the spectral viewer from 
(www.thermofisher.com). Pacific blue is brightly expressed in a violet laser. APC is brightly 
expressed in a red laser. APC-H7 is dimly expressed in a red laser. BV711, PE-Cy5.5 is 
moderately expressed in a blue laser. BV711 is brightly expressed on the violet laser. Alexa 
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Fluor 700 is dimly expressed on the red laser. PE-Cy7 is brightly expressed in the yellow 
green laser. The spectral overlap was compensated for from all the fluorochromes used in 
the panel, and their overlap was minimal except for BV711 and Alexa Fluor 700; APC-H7 
and PE-Cy7 shown in figure 3.8 (www.thermofisher.com). 
  
             
 
Figure 3.8. Shows emission spectra of fluorochromes using SpectraViewer 
(www.thermofisher.com). Emission spectra of Alexa Fluor 700 overlap with Brilliant violet 
711 they are in the same channel, and PE-Cy7 overlaps with APC-H7 in the spectral viewer. 
APC-fluor has similar spectral properties to APC-H7, Super bright 702 has similar spectral 
properties to BV 711 and hence they were compensated. 
 
3.5 The effects of IVIPs on Immune activation of T cells by flow cytometry assay 
Immune activation of T cells after exposure to IVIPs was investigated. Here, we used the 
expression of CD38, HLA-DR, and CCR5 on the surface of CD4+ or CD8+ T cells to 
represent the level of T cell activation. Representative flow plots from one of the 26 
participants for CD4 T cells (Figure 3.9) and CD8 T cells (Figure 3.10) are shown. For each 
participant, the negative control (R10 media), Snuff, Alum, and PHA (positive control) after 
3 hours of exposure are shown. 
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Figure 3.9. Representative flow cytometry dot plots showing impacts of IVIPs and PHA on 
the expression of cellular activation markers (CD38, HLA-DR) and CCR5 in CD4+ T cells 
After 3 hours of IVIP exposure at 37 °C. 
  
CD4+ T cells were expressing the CD38+ and HLA-DR+ similarly irrespective of the 
condition. For this reason, cells co-expressing HLA-DR, and CD38 were mainly used to 
mark highly activated cells. CCR5 is less expressed in the negative control, snuff, and alum 
exposure and it is not expressed in PHA stimulated cells. CD4+ T cells show significant 
CCR5 down-regulation following PHA stimulation (Figure 3.9). 
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Figure 3.10. Representative flow cytometry dot plots showing the activation status (CD38, 
HLA-DR and chemokine receptor (CCR5) expression in CD8+ T cells following stimulating 
with snuff, alum, PHA and R10 media for 3 hours at 37 °C. 
  
CD8+ T cells were expressing the CD38+ activation marker in all the conditions. CCR5+ is 
slightly expressed in the negative control, snuff, and alum, however, T cells show significant 
CCR5 down-regulation following PHA stimulation (Figure 3.10). HLA-DR+ CD8+ T cells 
were not expressed in all conditions therefore in CD8 T cells were not highly activated 
(HLA-DR+ CD38+). 
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Figure 3.11. Cross-sectional analysis of IVIPs exposure-specific T cell responses in 26 donors. 
Scatter plots showing the expression of CCR5+, CD38+, HLA-DR+ and CD38+ HLA-DR+ in 
CD4+ T cells (panel A) and in CD8+ T cells (panel B). PBMC samples were exposed to snuff, 
alum, and PHA for 3h, followed by staining and acquisition. Horizontal lines represent 
medians. Statistical comparisons were performed using the Wilcoxon test. Significant 
differences are shown by an asterisk (*) system (P < 0.05 *, P < 0.01 ** and P< 0.001***). 
       
In figure 3.11, the expression of CCR5+ is significantly lower in PHA stimulated cells when 
compared to the unstimulated cells (p=0.0001), snuff (p=0.0001) and alum (p=0.0002) 
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exposed cells in the CD4+ T cell population. Similarly, in the CD8+ T cell population the 
expression of the CCR5 biomarker is significantly lower in PHA stimulated cells when 
compared to the unstimulated cells (p=0.0001) and also when compared to the snuff 
(p=0.0001) and alum (p=0.0001) exposed cells.  In the CD4+ T cells the CCR5 biomarker is 
significantly higher in the snuff exposed cells compared to the unexposed cells (p=0.0483) 
and also when compared to the alum exposed cells (p=0.0446). 
 
The expression of CD38+ biomarker in the CD4+ T cell lymphocytes is significantly high in 
the PHA stimulation compared to the unstimulated cells (p=0.0001) and also when compared 
to the snuff (p=0.0061) and alum (p=0.0001) exposed cells. The CD38+ activation marker is 
significantly highly expressed in unexposed CD4 + T cells when compared to alum exposed 
CD4+ T cells (p=0.0051). In CD8+ T lymphocytes the CD38+ biomarker is significantly 
highly expressed in unexposed cells compared to the alum exposed cells (p=0.0185). 
 
HLA-DR+ biomarker in the CD4+ T lymphocytes is significantly highly expressed in the 
PHA stimulated cells when compared to the unstimulated cells (p=0.0003) and also when 
compared to snuff (p=0.0071) and alum (p=0.0003) exposed cells. In the CD8+ T 
lymphocytes the HLA-DR+ biomarker is also significantly highly expressed in PHA 
stimulated cells compared to unstimulated cells (p=0.0003) and also when compared to snuff 
(p=0.0060) and alum p=0.0023) exposed cells. Alum exposed CD8+ T cells also show a 
significantly higher expression of HLA-DR+ when compared to the unexposed cells 
(p=0.0348). 
 
In CD4+ T lymphocytes the dual expression of HLA-DR+CD38+ is significantly higher in 
PHA stimulated cells compared to the unstimulated cells (p=0.0001) and also when 
compared to the snuff (p=0.0046) and alum (p=0.0002) exposed cells. Similarly, in the CD8+ 
T lymphocytes the dual expression of HLA-DR+CD38+ is significantly higher in PHA 
stimulated cells compared to the unstimulated cells (p=0.0001) and also when compared to 
the snuff (p=0.0054) and alum (p=0.0028) exposed cells. Alum exposed CD8+ T cells also 
show a significantly higher expression of HLA-DR+CD38+ when compared to the unexposed 
cells (p=0.0208). 
 
 
64 
 
 
3.6 The effect of IVIPs exposure on biomarkers of inflammation using Bio-plex 
immunoassay  
Cytokine measurements were evaluated on thawed supernatant specimens collected 
following exposing cells with snuff alum and PHA for 3 hours at 37 °C. The cytokine 
concentrations were measured by using the Bio-Plex Pro Human cytokine assay (Bio-Rad) 
as per manufacturer instruction. Only 12 donors were included for this part of the study in 
duplicates. Eleven cytokines were evaluated: pro-inflammatory cytokines (interleukin (IL)-
1β, IL-6, tumour necrosis factor (TNF)–α and granulocyte-macrophage colony-stimulating 
factor (GM–CSF)); chemokines (interleukin (IL)-8, interferon gamma-induced protein (IP)-
10, monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)–1α 
and macrophage inflammatory protein (MIP)-1β)); Hematopoietic cytokines (interleukin 
(IL)-7) and regulatory cytokines (interleukin (IL)-10). 
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Figure 3.12. Shows Scatter plots comparison of chemokine concentrations in PBMC 
supernatants samples (n=12) harvested after cells were exposed to snuff, alum, PHA and R10 
media for 3 hours at 37 °C. Chemokine concentrations were measured in supernatants from 
cells left unstimulated (blue circles), snuff exposed cells (red circles), alum exposed (green 
circles), and PHA stimulated (purple circles). Black solid lines represent the median, upper 
and lower quartile. P value ≤ 0.05 was considered significant. Abbreviations: IL-8, 
interleukin-8; IP-10, interferon-γ inducible protein-10; MCP-1, monocyte chemoattractant 
protein-1; MIP-1α and β, macrophage inflammatory protein-1alpha and beta. 
 
In figure 3.12, PHA stimulation in all chemokines results to a significantly higher 
chemokine expression when compared to the unstimulated cells. Cells exposed to alum 
significantly had a higher expression of IL-8 chemokine compared to snuff exposed 
(p=0.0122). Cell exposure to PHA show a significantly higher expression of IL-8 when 
compared to both the alum and snuff exposure (p=0.0161) and (p=0.0010) respectively. 
IP-10 expression is significantly higher in cells exposed to alum compared to unexposed 
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cells (p=0.0039). Alum exposure results into a significantly higher expression of IP-10 
when compared to snuff exposure (p=0.0039). PHA stimulated cells show a significantly 
increased expression of IP-10 when compared to snuff exposed cells (p=0.0010). The 
expression of MCP-1 in alum exposed cells is significantly higher when compared to the 
unexposed cells (p=0.0024) and also when compared to snuff exposed cells (p=0.0015). 
PHA Stimulated cells results into a significantly higher expression of MCP-1 when 
compared to snuff exposed cells (p=0.0005). MIP-1α expression in the alum exposed cells 
is significantly higher compared to the unexposed cells (p=0.0005) and also when 
compared to snuff exposed cells (p=0.0005). PHA stimulated cells expressed significantly 
higher MIP-1α when compared to the snuff exposed cells (p=0.0010). MIP-1β expression 
in alum exposed cells is significantly higher when compared to the unexposed cells 
(p=0.0161) and also when compared to snuff exposed cells (p=0.0010). MIP-1β expression 
is significantly higher in PHA stimulation compared to snuff exposed cells (p=0.0010). 
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Figure 3.13. Shows Scatter plots comparison of pro-inflammatory (IL-1β, IL-6, TNF-α), 
hematopoietic (IL-7, GM-CSF) and regulatory (IL-10) cytokine concentrations in PBMC 
supernatants samples (n=12) harvested after cells were exposed to snuff, alum, PHA and R10 
media for 3 hours at 37 °C. Cytokine concentrations were measured in supernatants from 
cells left unstimulated (blue circles), snuff exposed cells (red circles), alum exposed cells 
(green circles), and PHA stimulated cells (purple circles). Black solid lines represent the 
median, upper and lower quartile. P value ≤ 0.05 was considered significant. Abbreviations: 
GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; TNF-α, 
tumour necrosis factor-alpha. 
 
In figure 3.13, PHA stimulation show significantly higher expression of pro-inflammatory 
cytokines IL-1β, IL-6, TNF-α (p=0.0029, p=0.0034 and p=0.0024) and regulatory cytokine 
–IL-10 (p=0.0269) when compared to the unstimulated cells. Alum exposed cells show 
significantly higher expression of IL-6 and TNF-α (p=0.0005) and (p=0.0020) respectively 
when compared to the unexposed cells. Alum exposure show significantly higher 
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expression of pro-inflammatory IL-1β, IL-6, TNF-α (p=0.0322, p=0.0005, p=0.0010), 
regulatory IL-10 (p=0.0322) and also of hematopoietic IL-7, GM-CSF (p=0.0005, 
p=0.0005) cytokines when compared to the snuff exposure. PHA stimulation show 
significantly higher expression of pro-inflammatory IL-1β, IL-6, TNF-α (p=0.0005, 
p=0.0010, p=0.0005), regulatory cytokine IL-10 (p=0.0010) and also hematopoietic IL-7 
(p=0.0088) cytokines when compared to snuff exposed cells. 
 
 
Figure 3.14. Unsupervised hierarchical clustering to show variation in cytokine expression by 
PBMCs cells following exposure to snuff (green boxes), alum (purple boxes), PHA (positive 
control; orange boxes) and unstimulated (blue boxes). Cytokine concentrations are indicated 
using a colour scale that ranges from blue (lowest) through pink to red (highest). The 
dendrogram above the heat map illustrates degrees of relatedness between cytokine profiles 
and different conditions. The dendrogram on the left-hand side of the heat map indicates 
relationships between the expression profiles of the 11 analysed cytokines. Supernatant 
samples are from 12 donors. Abbreviations: GM-CSF, granulocyte-macrophage colony-
stimulating factor; IL, interleukin; IP-10, interferon-γ inducible protein-10; MCP-1, 
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monocyte chemoattractant protein-1; MIP, macrophage inflammatory protein; TNF-a, 
tumour necrosis factor-alpha. 
 
In figure 3.14, PHA stimulations show an upregulated cytokine concentration and tended 
to cluster together however, one PHA sample shows poor cytokine expression. Exposure 
to alum also show an upregulated cytokine expression and tended to cluster together next 
to PHA. Snuff exposed cells and media (unstimulated/unexposed) cells show a moderate 
to low cytokine expression, respectively and tended to cluster together however, one media 
control sample shows high cytokine expression. 
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CHAPTER 4: DISCUSSION 
  
Many women use vaginal products for different reasons. However, the use of traditional or 
commercial vaginal insertion products may upset the normal pH in the vagina, which is 
important for maintaining the healthy vaginal immune barrier environment. Through the 
change of pH or direct mucosal trauma triggered by these products, inflammation, and 
activation of immune cells in response to trauma may lead to a higher risk of HIV and other 
infections. While IVIPs have been linked to increased risk of acquiring HIV (Allen et al., 
2010, Fonck et al., 2001), the exact mechanism by which the use of IVIPs predispose women 
to elevated levels of acquiring HIV is poorly understood. In this era of a high burden of HIV, 
it has become crucial to find ways to reduce HIV infections, especially in young women, 
because they are mostly infected with HIV (UNAIDS, 2018). It is therefore essential to 
evaluate the exposure effect of vaginal products used by young women on immune cells, to 
possibly identify the events that may lead to HIV acquisition risk. This study used a PBMC 
model to determine the exposure effects of intravaginal insertion products on biomarkers of 
inflammation and cellular immune activation in vitro. The vaginal products evaluated in this 
study were kuber (chewing tobacco which contains ~20% nicotine, cannabidiol and delta 9-
tetra cannabinol (THC); the primary ingredients is Indian hemp/marijuana), alum (Potassium 
aluminium sulfate), rose water (flavoured water made from steeping rose petals into the 
water, used as a vaginal douche) and snuff (tobacco which is made from ground or pulverized 
tobacco leaves and contains nicotine). Alum and snuff were selected for thorough assessment 
in this study because of their common use and also due to budget constraints.  
  
IVIPs have been suspected of causing biochemical changes in the vagina (Van de Wijgert et 
al.,2000), they increase pH in the vagina, therefore, encouraging the growth of 
microorganisms associated with bacterial vaginosis which is evidently linked to increased 
risk of HIV infection acquisition in women (Atashili et al., 2008). Hence, it was crucial to 
evaluate the pH of intravaginal insertion products. The stock solution of Alum, rose water 
and savlon were acidic (pH of 2.62, 4.21 and 6.00 respectively). The results from this study 
confirm the hypothesis that some vaginal products may alter the normal vaginal pH of 4.5.  
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A study conducted by Cohen (1969), which showed that some Candida species are able to 
grow at a pH of 2 and lower and they can acidify the environment as a strategy to damage 
host tissues (Naglik et al., 2003). 
 
Exposure of cells to alum and savlon resulted in high percentage of cell death, indicating the 
high toxicity effect of these products. The high toxicity of alum and savlon would imply that 
damage is inflicted by using these products unless they are diluted extensively (which is 
unlikely in real life). These IVIPs may cause physical damage to the epithelial layer and 
create an environment that favours the survival and growth of opportunistic organisms by 
exposing resident cells to damage-associated molecular pattern molecules (DAMPs) 
therefore leading to enhanced inflammation. One of the motivations behind the use of alum 
has been the dry sex effect (Humphries et al., 2019) and dry sex causes vaginal tears which 
are linked to increased risk of HIV acquisition (Dosekun and Fox, 2010). Hence, the change 
in the vaginal pH caused by alum together with the dry sex effect may predispose women to 
heightened risk of HIV acquisition, because the vaginal epithelium tissue damage would 
induce a protective inflammatory response and this response would bring more immune cells 
to the damaged area to help repair the damaged tissue while providing a doorway or an easy 
entry of the HIV virus into the female genital tract. Physical damage to vaginal epithelial 
cells could also mimic abrasions and allow leakage of IVIPs into underlying tissues. 
Aluminium hydroxide (ALOH) is used as an adjuvant in vaccines despite it toxicity. It has 
been shown that alum injection induces inflammation (White et al., 1955). However, it is 
unclear how alum triggers the inflammatory response, some believe that alum causes 
cytotoxicity leading to the leakage of DAMPs that eventually causes inflammation through 
TLR. A study by Hanfen et al., (2007) demonstrated that alum is capable of activating 
caspase-1 by inducing the release of mature IL-1β and IL-18 in cells that are activated by 
the TLR agonist. However, activation of caspase-1 is believed to require phagocytosis of 
alum particles. They further demonstrated that alum inhibited IP-10 production while it up 
regulated IL-10 production. There are many different forms of alum that are used in human 
studies, in this study we used KAL(SO4)2, in vaccines they use Aluminium hydroxide 
(ALOH) (Li et al., 2007), while in water purification they use aluminium hydro(Oxide) (AO) 
prepared from aluminium sulfate (Mulugeta et al., 2014). We don’t know if the mechanism 
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of action of all the different forms of alum is the same or not, however, in all these different 
forms alum is acknowledged to be toxic. Future studies can compare the different forms of 
alum to determine if their mechanism of action is the same or if there are differences in how 
they work and their uses. 
 
Snuff and kuber on the other hand, were quite basic (less toxic) stock solution pH 9.11 and 
8.21 respectively. A basic pH may cause clearing of lactic acid-producing bacteria resulting 
in an unstable vaginal microflora. The disturbance of the normal vaginal microflora can lead 
to the up-regulation of immunological responses, causing inflammation in the vagina. 
Disequilibrium in the vaginal microbiota is termed BV, and it has been associated with more 
than three-fold increased risk of acquiring HIV infection (Atashili et al., 2008, Cohen et al., 
2012). Women use IVIPs usually before a sexual encounter and in this case snuff may buffer 
the vaginal microenvironment and this alone may be detrimental to women’s health, after a 
sexual encounter the addition of semen into the woman’s vagina that was pre-treated with 
snuff may cause a double negative effect, because semen also neutralizes the vagina (Du 
Plessis et al., 2013) which may also further increase the risk of infection either by changing 
immune responses or creating favourable environment for STIs and other infections such as 
BV. 
  
Following full optimization of a multiple colour flow cytometry panel, the CCR5 expression 
and the activation status of IVIP exposed T cells was examined by evaluating the expression 
of CCR5, HLA-DR, CD38 in T cells after no stimulation/IVIP exposure (negative control) 
and exposure to optimal concentrations of snuff, alum, and PHA (positive control). The 
cervicovaginal mucosa is lined with epithelial cells that are not susceptible to infection 
(Dezzutti et al., 2001). The vaginal epithelium has flattened squamous epithelial cells 
comprising of immune cells upon a breach, HIV can cross the physical barrier through breaks 
in the epithelium (Miller et al., 2005) and through microtears incurred as a result of sexual 
intercourse associated with vaginal trauma that may be exacerbated by an IVIP use. HIV 
penetrates the epithelium rapidly, and thereafter it has access to numerous susceptible target 
cells that lie within and below the epidermal layer, such as macrophages, dendritic cells, and. 
CD4 T cells that express CCR5 are the main target of HIV in the mucosa (Li et al., 2015). 
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Increased susceptibility to HIV infection of activated CD4-T cells has been correlated with 
increased CCR5 expression (Meditz et al., 2011). Hyperimmune activation of T cells, 
effected by PHA stimulation, was accompanied by a reduced expression of CCR5 in T cells 
in this study. Contrary snuff exposed cells results in significantly more CCR5 expression in 
CD4+ T cells, compared to unstimulated cells, alum and PHA stimulations. Paxton et al. 
(1998) associated low CCR5 cell surface expression after PHA stimulation with high levels 
of β-chemokines. Hence, the CCR5 cell surface receptor gets internalized after binding to its 
natural ligands (Alkhatib et al., 1997), which are upregulated upon activation and high β-
chemokine levels may consequently result in reduced CCR5 expression. These previous 
findings, therefore, suggest that CCR5 expression and levels of β-chemokines should be used 
together to determine the ultimate levels of CCR5 cell surface expression. The β-chemokines 
measured in this study were MIP-1α and MIP-1β, and these were both significantly more 
produced following exposure to alum and PHA, compared to snuff stimulated and 
unstimulated cells, and this might explain the lower surface expression of CCR5 in PHA and 
alum stimulated cells. PBMC exposure to snuff, on the other hand, led to significantly higher 
expression of CCR5 by CD4 T cells, and in addition, MIP-1α and MIP-1β were both 
significantly less produced following snuff exposure. In this study, it was shown that higher 
expression of CCR5 expressed by CD4 T cells after exposure to IVIPs was only evident 
when β-chemokines levels were low, and this was the case with cells exposed to snuff. As 
shown in Appendix A (Table 1), there was a weak but significant negative association 
between MIP-1β and CCR5 expression by CD4+ T cells which were unstimulated (r=-0.165, 
p=0.01), exposed to snuff (r=-0.069, p=0.016) and alum (r=-0.142, p=0.015). This 
association between MIP-1β and CCR5 expression was not significant in CD4+ T cells 
stimulated with PHA (APPENDIX A, Table 1). This may be due to the hyper activation 
effect of PHA or a small sample size, since there were only 12 donors with matched data for 
CCR5 expression and chemokine concentrations.  
  
To assess the T cell activation effect by IVIPs, the CD38 and HLA-DR activation markers 
were measured because these cell surface markers are upregulated upon activation, each at 
a different stage of the activation process.CD38 marker is an early T cell activation marker 
while HLA-DR is a late T cell activation marker (Bajnok et al., 2017, Tenca et al., 2003). 
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Dual expression of CD38 and HLA-DR was also assessed because these cells are considered 
to be highly activated cells and may be more appropriate for evaluating the effect of IVIPs 
on immune activation. Dual expression of CD38 and HLA-DR by CD4+ T cells and CD8+ T 
cells was significantly higher in PHA stimulated cells. Similarly, CD8+ T cells exposed to 
alum, had significantly higher dual expression of CD38 and HLA-DR compared to 
unstimulated cells, indicating the presence of highly activated CD8+ T cells following alum 
exposure. CD38 and HLA-DR dual expression by CD8+ T cells did not change significantly 
in snuff stimulated cells compared to unstimulated cells. The dual expression of CD38 and 
HLA-DR on T cells determined the hyperactivation status, and alum is therefore associated 
with hyperactivation of CD8+ T cells because of the co-expression of CD38 and HLA-DR 
that was significantly increased in alum stimulated CD8+ T cells. Alum seemed to enhance 
the activity of CD8 T cells in this model, and this may be associated with its adjuvant 
properties.  
  
In addition to alum inducing higher levels of immune activation (especially in the CD8+ T 
cell population) compared to unstimulated cells and snuff, alum induced significantly higher 
levels of inflammation (measured by expression of a broad panel of inflammatory, anti-
inflammatory and haematopoietic cytokines). The comparatively elevated levels of 
inflammation in alum stimulated cells could be due to several factors such as the immunity-
boosting effect of alum. The adjuvant effects of alum have been attributed to its ability to 
prolong antigen exposure to the immune system. However, from the results observed in this 
study and other studies (Kool et al., 2008, Li et al., 2008, McKee et al., 2009) it is clear that 
alum can be recognized by the innate immune system leading to upregulation of several pro-
inflammatory cytokines and chemokines.  
 
Cytokines and chemokines (except IL-1β and IL-10) were significantly elevated in alum 
stimulated cells, compared to snuff and unstimulated cells. The cytokine concentrations in 
alum stimulated cells were in most cases, similar to the concentrations of cytokines in PHA 
(positive control) stimulated cells. A number of studies have investigated how alum achieves 
these inflammatory effects. A number of in vitro experiments have shown that alum activates 
the NLRP3 inflammasome in macrophages which, in turn, activates caspase-1 and the 
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consequent production of cytokines (Eisenbarth et al., 2008, Kool et al., 2008, Li et al., 
2008). A study byMcKee et al. (2009), showed that many pro-inflammatory cytokines and 
chemokines are rapidly produced in vivo after exposure to alum. Eosinophils, neutrophils, 
monocytes, NK cells, NKT cells, and DCs, are rapidly recruited to the site of injection. 
Similarly, a strong inflammatory state was associated with alum exposure in this study. Cells 
exposed to snuff, on the other hand, showed a lower cytokine and chemokine expression and 
its effect was not statistically different from unstimulated cells. 
 
The observations made in this study may explain an increase in inflammatory cytokines 
previously seen in women who had reported using products other than water for intravaginal 
practices (Kyongo et al., 2015). The use of IVIPs, particularly alum, could possibly, be 
associated with vaginal inflammation, which has been associated with a high risk of 
acquiring HIV infection (Masson et al., 2015). HIV infects and replicates more efficiently in 
an inflammatory environment (Narimatsu et al., 2005). Recruitment of activated cells after 
the use of alum may increase susceptibility to HIV infection. MIP-1α and MIP-1β are the 
CCR5 ligands, and they are upregulated upon activation (Lederman et al., 2006), and they 
inhibit the entry and fusion of HIV by downregulating the chemokine receptor (Moody et 
al., 2010). This can be used to explain the result discussed above of CCR5 downregulation, 
and chemokine elevation in alum stimulated cells. However, these chemotactic chemokines 
also play a huge role in inflammation, which is known to recruit T cells that are preferentially 
infected by HIV, especially CD4 T cells that are attracted by MIP-1β (Bhavsar et al., 2014). 
Pro-inflammatory cytokines play a role in responding to foreign antigens; however, these 
cytokines in large quantities could potentially induce tissue damage (Czaja, 2014). We noted 
elevated pro-inflammatory cytokines (TNF-α, IL-8, IL-6, GM-CSF) after exposure to alum 
thus, the use of alum may exert some damage in the vaginal tissue. The effect of IVIPs on 
the vaginal tissue would be influenced by the cytokine levels and how long it takes for 
women to douche with these products and the frequency of use of these products. The PBMC 
model used in this study does not show any effect of snuff on the immunological markers 
which were investigated in this study, therefore we are unable to draw conclusions about 
snuff, although the pH of snuff is a lot higher than the ideal vaginal pH, which may exert a 
negative effect on the vaginal microenvironment as has been discussed above. Snuff also 
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seemed to increase the expression of CCR5 receptors on CD4+ T cells, which may likely 
increase the risk of HIV acquisition.  
 
Given that the experimental work done in this study was on PBMCs and not vaginal cell 
lines, we are unable to assign the effects of alum douching on vaginal cells conclusively. We 
acknowledge that PBMCs may not behave in the same manner as vaginal cell lines. PBMCs 
are one of the best models for assessing immunological responses and their characteristics 
are very interesting because they are primary cells, they are not immortalized, have the 
genetic backgrounds of real patients, and they are easy to isolate from whole blood 
(Burczynski and Dorner, 2006). The limitation is that PBMCs alone cannot completely 
mimic what would take place in vivo. There are several other limitations, such as the amount 
of the products used by women could not be established as this varies from individuals. The 
concentrations of IVIPs used and the duration of exposure were solely based on cell viability. 
The duration of IVIP use by women is not known as it also varies from individuals. 
  
In conclusion, this study is the first of its kind to identify possible mechanisms that link 
intravaginal insertion products and HIV. Alum, in particular, was more inflammatory 
compared to snuff. Future research can extend the current pilot study by looking at the effect 
of intravaginal insertion products on the actual vaginal cells. Knowledge from this work and 
future studies is crucial in developing new female-initiated interventions for preventing HIV 
acquisition through sexual mucosal transmission taking into account the use and impacts of 
IVIPs. Since a lot of women in South Africa, particularly in KZN, engage in intravaginal 
practices, education on vaginal health is critical. Women need to be educated about IVIPs 
and their possible impact on the vaginal flora, vaginal PH, epithelial damage and 
inflammation because women naively engage in intravaginal practices to merely have 
control over their sexuality and to improve hygiene without realizing the potentially harmful 
nature of these products and the negative effect these may exert on their vaginas and overall 
wellbeing. 
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APPENDIX A: RELATIONSHIP BETWEEN CD4+ T CELL IMMUNE 
ACTIVATION AND BIOMARKERS OF INFLAMMATION 
 
Table- 1. Spearman’s correlation observed between chemokines and CCR5 expression levels 
by CD4+ T cells in 12 donor PBMCs exposed to IVIPs. 
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Table- 2. Spearman’s correlation observed between cytokines and CCR5 expression levels by 
CD4+ T cells in 12 donor PBMCs exposed to IVIPs 
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Table- 3. Spearman’s correlation observed between chemokines and activation marker 
expression levels by CD4+ T cells in 12 donor PBMCs exposed to IVIPs. 
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Table- 4. Spearman’s correlation observed between cytokines and activation marker 
expression levels by CD4+ T cells in 12 donor PBMCs exposed to IVIPs 
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APPENDIX B: ETHICAL APPROVAL  
 
 
